[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fTgi3KFOESNXsB3P2CsB5XnFthxmMQWpDM9zF0eK49w4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"UNC Lineberger Comprehensive Cancer Center",[4],409,false,119,1,117781,76,224,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Breast Cancer",66,{"name":18,"count":19},"Cancer",28,{"name":21,"count":22},"Lymphoma",17,{"name":24,"count":22},"Lung Cancer",{"name":26,"count":27},"Colorectal Cancer",15,{"name":29,"count":30},"Bladder Cancer",14,{"name":32,"count":30},"Prostate Cancer",{"name":34,"count":35},"Endometrial Cancer",12,[37,42,47,52,57,61,66,71,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT02663297","Administration of T Lymphocytes for Prevention of Relapse of Lymphomas","2021-01-15","ATLCAR.CD30 cells",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03174275","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","2022-02-02","Durvalumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03264131","BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma","2023-12-15","Brentuximab Vedotin",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03978624","Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer","2024-03-25","Pembrolizumab",{"nctId":58,"briefTitle":59,"date":60,"intervention":46},"NCT03529422","Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN","2024-07-01",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04585893","Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi","2024-08-30","Rituximab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT03672318","Study of ATLCAR.CD138 Cells for Relapsed\u002FRefractory Multiple Myeloma","2024-10-16","CAR138 T Cells",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT04670068","Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian","2024-12-19","CAR.B7-H3",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04134325","Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed\u002FRefractory Hodgkin Lymphoma","2025-04-01","Nivolumab",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT04548648","A Pilot Study of Acalabrutinib in Relapsed\u002FRefractory Primary and Secondary CNS Lymphomas","2025-05-14","Acalabrutinib",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,286,387,522,569,706,762,797,837,859,893,924,1057,1140,1181,1214,1247,1278,1313,1360,1382,1423,1451,1473,1507,1532,1558,1576,1594,1612,1630,1648,1669,1696,1714,1732,1763,1781,1799,1817,1835,1853,1871,1898,1923,1941,1959,1982,2000,2018,2043,2069,2087,2114,2136,2166,2215,2233,2253,2271,2289,2307,2331,2356,2374,2392,2410,2428,2446,2464,2496,2514,2536,2582,2605,2630,2657,2688,2713,2765,2812,2888,2940,2991,3021,3057,3088,3118,3160,3189,3215,3241,3267,3298,3330,3357,3384,3421,3449,3471,3493,3515,3543,3565,3604,3635,3657,3679,3701,3728,3762,3784,3802,3826,3844,3862,3889,3917,3939,3957,3975,3993,4019,4037,4059,4086,4104,4122,4140,4158,4182,4200,4225,4243,4261,4279,4297,4320,4347,4365,4383,4409,4427,4445,4463,4490,4508,4526,4550,4575,4593,4611,4635,4659,4685,4703,4721,4739,4757,4793,4825,4858,4895,4913,4931,4957,4981,4999,5023,5041,5066,5084,5107,5125,5143,5161,5179,5203,5221,5239,5257,5275,5293,5311,5329,5347,5369,5391,5416,5434,5452,5476,5515,5547,5578,5600,5621,5639,5664,5682,5706,5732,5750,5781,5799,5817,5835],{"intervention":95,"totalTrials":96,"cells":97},"Fludarabine",13,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":212,"PHASE3":265,"PHASE4":267,"NA":269},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":211,"soonestReadout":74},[103,119,132,150,158,174,198],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":116},"NCT06305299","Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells","RECRUITING",[88],"2036-04","2024-07-29",27,[112,113,114,115],"Ovary Neoplasm","Ovarian Cancer","Epithelial Ovarian Cancer","Recurrent",[117,118,95],"iC9-CAR.B7-H3 T cells","Cyclophosphamide",{"nctId":120,"briefTitle":121,"status":106,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":130},"NCT03721068","Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed\u002FRefractory Neuroblastoma or Relapsed\u002FRefractory Osteosarcoma",[88],"2030-05-19","2044-06-19","2019-02-19",18,[128,129],"Neuroblastoma","Osteosarcoma",[131,118,95],"iC9.GD2.CAR.IL-15 T-cells",{"nctId":133,"briefTitle":134,"status":106,"phases":135,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":147},"NCT04223765","Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed\u002FRefractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma.",[88],"2028-03-22","2043-03-22","2020-11-12",20,[141,142,143,144,145,146],"Mantle Cell Lymphoma","Follicular Lymphoma","Splenic Marginal Zone Lymphoma","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Nodal Marginal Zone Lymphoma","Indolent Non-hodgkin Lymphoma",[148,95,118,149],"CAR.k.28","Bendamustine",{"nctId":72,"briefTitle":73,"status":151,"phases":152,"primaryCompletion":74,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"ACTIVE_NOT_RECRUITING",[88],"2030-02","2021-01-27",4,[114],[75,95,118],{"nctId":159,"briefTitle":160,"status":106,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":170},"NCT06347068","Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells",[88],"2026-05","2028-05","2024-06-27",42,[15,167,168,169],"Relapse","Resistant Cancer","Triple Negative Breast Cancer",[171,172,173],"iC9-CAR.B7-H3 T Cell Therapy","cyclophosphamide","fludarabine",{"nctId":175,"briefTitle":176,"status":151,"phases":177,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":195},"NCT03602157","Study of CAR-T Cells Expressing CD30 and CCR4 for r\u002Fr CD30+ HL and CTCL",[88],"2025-12-16","2039-11-04","2018-12-12",43,[21,183,184,185,186,187,188,189,190,191,192,193,194],"Immune System Diseases","Immunoproliferative Disorders","Lymphatic Diseases","Lymphoproliferative Disorders","Neoplasms","Cutaneous Lymphoma","Cutaneous Anaplastic Large Cell Lymphoma","Mycosis Fungoides","Sezary Syndrome","Lymphomatoid Papulosis","Cutaneous T Cell Lymphoma","Gray Zone Lymphoma",[196,197,149,95],"ATLCAR.CD30.CCR4 cells","ALTCAR.CD30 cells",{"nctId":199,"briefTitle":200,"status":151,"phases":201,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT03696784","Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma",[88],"2025-08-31","2040-07-31","2019-03-12",19,[21,207,183,184,185],"Lymphoma, B-Cell",[209,149,95,210,118],"iC9-CAR19 T cells","AP1903",7,{"trials":213,"activeCount":264,"soonestReadout":218},[214,226,240,253],{"nctId":215,"briefTitle":216,"status":151,"phases":217,"primaryCompletion":218,"completion":219,"start":220,"enrollment":22,"conditions":221,"interventions":223},"NCT03016377","Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed\u002FRefractory ALL",[88,89],"2025-09-12","2037-09-12","2012-03-22",[222,183,184],"Acute Lymphoblastic Leukemia",[224,225,118,95],"iC9-CAR19 cells","Rimiducid",{"nctId":227,"briefTitle":228,"status":229,"phases":230,"primaryCompletion":178,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":237},"NCT05634785","CD30 CAR for CD30+ NSGCT","COMPLETED",[89],"2025-12-18","2022-12-09",2,[235,236],"Germ Cell Tumor","Nonseminomatous Germ Cell Tumor",[238,239,95],"ATLCAR.CD30 Cells","Cyclophosphamid",{"nctId":241,"briefTitle":242,"status":106,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":251},"NCT06096038","Autologous CAR-T Cells Targeting CSPG4 in Relapsed\u002FRefractory HNSCC",[88,89],"2026-09-01","2028-08-01","2024-04-05",33,[249,167,115,250],"Head and Neck Cancer","Refractory Cancer",[118,95,252],"Cell Therapy",{"nctId":254,"briefTitle":255,"status":106,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":139,"conditions":260,"interventions":262},"NCT04083495","CD30 CAR for Relapsed\u002FRefractory CD30+ T Cell Lymphoma",[89],"2028-02-23","2038-08","2019-09-17",[261],"Peripheral T Cell Lymphoma",[263,149,95,118],"ATLCAR.CD30 T cells",3,{"trials":266,"activeCount":100},[],{"trials":268,"activeCount":100},[],{"trials":270,"activeCount":100},[271,280],{"nctId":272,"briefTitle":273,"status":274,"phases":275,"conditions":276,"interventions":278},"NCT03914885","Compassionate Use Re-Infusion of ATLCAR.CD30","NO_LONGER_AVAILABLE",[],[277],"Hodgkin Lymphoma, Adult",[279,149,95],"ATLCAR.CD30",{"nctId":281,"briefTitle":282,"status":274,"phases":283,"conditions":284,"interventions":285},"NCT03594162","Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch",[],[222,183,184],[224,210,118,95],{"intervention":118,"totalTrials":30,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":327,"PHASE3":377,"PHASE4":379,"NA":381},{"trials":289,"activeCount":100},[],{"trials":291,"activeCount":326,"soonestReadout":74},[292,296,300,304,314,318,322],{"nctId":104,"briefTitle":105,"status":106,"phases":293,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":294,"interventions":295},[88],[112,113,114,115],[117,118,95],{"nctId":120,"briefTitle":121,"status":106,"phases":297,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":298,"interventions":299},[88],[128,129],[131,118,95],{"nctId":133,"briefTitle":134,"status":106,"phases":301,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":302,"interventions":303},[88],[141,142,143,144,145,146],[148,95,118,149],{"nctId":305,"briefTitle":306,"status":229,"phases":307,"primaryCompletion":308,"completion":308,"start":309,"enrollment":205,"conditions":310,"interventions":312},"NCT00719173","Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer",[88],"2010-10","2005-08",[15,311],"Nausea and Vomiting",[313,172],"aprepitant",{"nctId":72,"briefTitle":73,"status":151,"phases":315,"primaryCompletion":74,"completion":153,"start":154,"enrollment":155,"conditions":316,"interventions":317},[88],[114],[75,95,118],{"nctId":159,"briefTitle":160,"status":106,"phases":319,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":320,"interventions":321},[88],[15,167,168,169],[171,172,173],{"nctId":199,"briefTitle":200,"status":151,"phases":323,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":324,"interventions":325},[88],[21,207,183,184,185],[209,149,95,210,118],6,{"trials":328,"activeCount":264,"soonestReadout":218},[329,339,352,356,360,373],{"nctId":330,"briefTitle":331,"status":229,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":338},"NCT02768701","Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer",[89],"2022-05-01","2023-05-01","2016-10-18",40,[169],[56,118],{"nctId":340,"briefTitle":341,"status":229,"phases":342,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":348},"NCT00006110","Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer",[89],"2012-03","2013-04","1998-12",82,[15],[349,172,350,351],"trastuzumab","doxorubicin hydrochloride","paclitaxel",{"nctId":215,"briefTitle":216,"status":151,"phases":353,"primaryCompletion":218,"completion":219,"start":220,"enrollment":22,"conditions":354,"interventions":355},[88,89],[222,183,184],[224,225,118,95],{"nctId":241,"briefTitle":242,"status":106,"phases":357,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":358,"interventions":359},[88,89],[249,167,115,250],[118,95,252],{"nctId":361,"briefTitle":362,"status":229,"phases":363,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":369},"NCT00003392","High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer",[89],"2002-08","2003-01","1997-09",61,[15],[370,371,172,372,351],"filgrastim","carboplatin","melphalan",{"nctId":254,"briefTitle":255,"status":106,"phases":374,"primaryCompletion":257,"completion":258,"start":259,"enrollment":139,"conditions":375,"interventions":376},[89],[261],[263,149,95,118],{"trials":378,"activeCount":100},[],{"trials":380,"activeCount":100},[],{"trials":382,"activeCount":100},[383],{"nctId":281,"briefTitle":282,"status":274,"phases":384,"conditions":385,"interventions":386},[],[222,183,184],[224,210,118,95],{"intervention":56,"totalTrials":35,"cells":388},{"EARLY_PHASE1":389,"PHASE1":410,"PHASE2":426,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":390,"activeCount":9,"soonestReadout":79},[391,400],{"nctId":77,"briefTitle":78,"status":151,"phases":392,"primaryCompletion":79,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":399},[87],"2037-07-07","2019-09-01",10,[397,398],"Relapsed Hodgkin Lymphoma","Refractory Hodgkin Lymphoma",[80,56],{"nctId":401,"briefTitle":402,"status":403,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":264,"conditions":407,"interventions":409},"NCT03694834","Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer","TERMINATED",[87],"2023-10-23","2019-03-29",[34,408],"Uterine Cancer",[56],{"trials":411,"activeCount":100},[412],{"nctId":413,"briefTitle":414,"status":415,"phases":416,"primaryCompletion":417,"completion":418,"start":419,"enrollment":326,"conditions":420,"interventions":424},"NCT04266730","Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab","SUSPENDED",[88],"2027-06-01","2033-06-01","2027-05-20",[421,422,423],"Squamous Cell Lung Cancer","Squamous Non-small Cell Lung Cancer","Squamous Cell Carcinoma of Head and Neck",[425,56],"PANDA-VAC",{"trials":427,"activeCount":264,"soonestReadout":55},[428,435,439,450,462,471,487,496,506],{"nctId":53,"briefTitle":54,"status":151,"phases":429,"primaryCompletion":55,"completion":430,"start":431,"enrollment":139,"conditions":432,"interventions":433},[89],"2026-11-22","2020-09-23",[29],[56,434],"Entinostat",{"nctId":330,"briefTitle":331,"status":229,"phases":436,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":437,"interventions":438},[89],[169],[56,118],{"nctId":440,"briefTitle":441,"status":442,"phases":443,"primaryCompletion":163,"completion":163,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT07484139","H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)","NOT_YET_RECRUITING",[89],"2026-06",26,[447,249],"Oral Cavity Squamous Cell Carcinoma",[449,56],"XL092",{"nctId":451,"briefTitle":452,"status":151,"phases":453,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":459},"NCT05366166","Pembrolizumab Plus Olaparib in LA-HNSCC",[89],"2027-01-21","2030-11-21","2022-09-02",45,[423],[56,460,461],"Olaparib","Cisplatin",{"nctId":463,"briefTitle":464,"status":229,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":139,"conditions":468,"interventions":470},"NCT02684461","Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel",[89],"2021-11-19","2016-09-13",[469],"Non Small Cell Lung Cancer",[56],{"nctId":472,"briefTitle":473,"status":229,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":485},"NCT03620019","Denosumab + PD-1 in Subjects With Stage III\u002F IV Melanoma",[89],"2023-04-15","2023-08-15","2018-09-10",25,[480,481,482,483,484],"Melanoma Stage Iii","Melanoma Stage Iv","Melanoma","Melanoma (Skin)","Cutaneous Melanoma",[486,56,80],"Denosumab",{"nctId":488,"briefTitle":489,"status":229,"phases":490,"primaryCompletion":491,"completion":492,"start":493,"enrollment":110,"conditions":494,"interventions":495},"NCT03089606","Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker",[89],"2021-04-01","2023-07-01","2017-04-19",[482],[56],{"nctId":497,"briefTitle":498,"status":229,"phases":499,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":505},"NCT02609503","Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin",[89],"2019-12-23","2023-11-20","2016-05-16",29,[249],[56],{"nctId":507,"briefTitle":508,"status":229,"phases":509,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":515},"NCT03765229","An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III\u002FIV Melanoma",[89],"2022-12-31","2023-07-31","2019-03-22",11,[482],[434,56],{"trials":517,"activeCount":100},[],{"trials":519,"activeCount":100},[],{"trials":521,"activeCount":100},[],{"intervention":149,"totalTrials":326,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":540,"PHASE3":559,"PHASE4":561,"NA":563},{"trials":525,"activeCount":100},[],{"trials":527,"activeCount":264,"soonestReadout":202},[528,532,536],{"nctId":133,"briefTitle":134,"status":106,"phases":529,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":530,"interventions":531},[88],[141,142,143,144,145,146],[148,95,118,149],{"nctId":175,"briefTitle":176,"status":151,"phases":533,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":534,"interventions":535},[88],[21,183,184,185,186,187,188,189,190,191,192,193,194],[196,197,149,95],{"nctId":199,"briefTitle":200,"status":151,"phases":537,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":538,"interventions":539},[88],[21,207,183,184,185],[209,149,95,210,118],{"trials":541,"activeCount":9,"soonestReadout":257},[542,555],{"nctId":543,"briefTitle":544,"status":229,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":554},"NCT01234467","Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma",[89],"2013-12","2016-08","2011-03",23,[551,552,553,21],"Diffuse Large B-Cell Lymphoma","Lymphoma, Diffuse Large-Cell","Diffuse Large-Cell Lymphoma",[149,65],{"nctId":254,"briefTitle":255,"status":106,"phases":556,"primaryCompletion":257,"completion":258,"start":259,"enrollment":139,"conditions":557,"interventions":558},[89],[261],[263,149,95,118],{"trials":560,"activeCount":100},[],{"trials":562,"activeCount":100},[],{"trials":564,"activeCount":100},[565],{"nctId":272,"briefTitle":273,"status":274,"phases":566,"conditions":567,"interventions":568},[],[277],[279,149,95],{"intervention":461,"totalTrials":513,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":601,"PHASE3":700,"PHASE4":702,"NA":704},{"trials":572,"activeCount":100},[],{"trials":574,"activeCount":100},[575,590],{"nctId":576,"briefTitle":577,"status":229,"phases":578,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT00573690","Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors",[88],"2009-06","2011-02","2007-09",31,[584],"Unspecified Adult Solid Tumor, Protocol Specific",[371,586,587,588,589],"cisplatin","etoposide","pemetrexed disodium","sorafenib tosylate",{"nctId":591,"briefTitle":592,"status":229,"phases":593,"primaryCompletion":594,"completion":595,"start":596,"enrollment":35,"conditions":597,"interventions":599},"NCT02585973","Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate\u002FHigh Risk HNSCC",[88],"2019-06-14","2021-06-23","2015-10-26",[598],"Carcinoma, Squamous Cell of Head and Neck",[600,461],"AZD1775",{"trials":602,"activeCount":233,"soonestReadout":45},[603,616,624,635,648,664,673,684,688],{"nctId":604,"briefTitle":605,"status":229,"phases":606,"primaryCompletion":607,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":615},"NCT02281955","De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study",[89],"2019-11","2024-11-24","2014-08",115,[612,613,614],"Carcinoma, Squamous Cell","Head and Neck Neoplasms","Oropharyngeal Neoplasms",[461],{"nctId":617,"briefTitle":618,"status":229,"phases":619,"primaryCompletion":620,"completion":607,"start":621,"enrollment":457,"conditions":622,"interventions":623},"NCT01530997","De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca",[89],"2014-11","2012-02-07",[612,613,614],[461],{"nctId":625,"briefTitle":626,"status":229,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":445,"conditions":631,"interventions":633},"NCT00002984","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus",[88,89],"2006-05","2007-01","1997-03",[632],"Esophageal Cancer",[586,634,351],"fluorouracil",{"nctId":636,"briefTitle":637,"status":229,"phases":638,"primaryCompletion":639,"completion":640,"start":641,"enrollment":336,"conditions":642,"interventions":644},"NCT01612351","Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery",[89],"2016-11","2025-05-19","2012-06",[249,643],"Squamous Cell Carcinoma of the Head and Neck",[645,646,647,461,461],"Carboplatin","Paclitaxel","Lapatinib",{"nctId":649,"briefTitle":650,"status":403,"phases":651,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":658},"NCT05498220","Polatuzumab Vedotin With R-GDP in Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma",[89],"2025-03-07","2025-10-03","2023-02-17",5,[657],"Diffuse Large B-cell Lymphoma",[659,65,660,661,461,662,663],"Polatuzumab vedotin","Hyaluronidase","Gemcitabine","Dexamethasone","GCSF",{"nctId":665,"briefTitle":666,"status":229,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":672},"NCT03077243","P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC",[89],"2022-12-14","2016-12",195,[612,613,614],[461],{"nctId":674,"briefTitle":675,"status":229,"phases":676,"primaryCompletion":677,"completion":678,"start":679,"enrollment":30,"conditions":680,"interventions":681},"NCT00520091","Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer",[89],"2006-11","2010-09","2005-03",[632],[682,461,683],"CPT- 11","Celecoxib",{"nctId":451,"briefTitle":452,"status":151,"phases":685,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":686,"interventions":687},[89],[423],[56,460,461],{"nctId":43,"briefTitle":44,"status":151,"phases":689,"primaryCompletion":45,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":698},[89],"2027-02-02","2017-12-19",39,[612,694,695,696,697,632],"Oral Cancer","Oropharynx Cancer","Larynx Cancer","Lip Cancer",[46,645,699,461],"Nab-paclitaxel",{"trials":701,"activeCount":100},[],{"trials":703,"activeCount":100},[],{"trials":705,"activeCount":100},[],{"intervention":662,"totalTrials":155,"cells":707},{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":756,"PHASE4":758,"NA":760},{"trials":709,"activeCount":100},[],{"trials":711,"activeCount":100},[],{"trials":713,"activeCount":233,"soonestReadout":743},[714,726,739,752],{"nctId":715,"briefTitle":716,"status":106,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":723},"NCT05145400","Isa-Rd for Frail and\u002For Much Older Patients With Newly Diagnosed Multiple Myeloma",[89],"2033-05-28","2022-02-18",50,[722,18],"Multiple Myeloma",[724,725,662],"Isatuximab","Lenalidomide",{"nctId":727,"briefTitle":728,"status":415,"phases":729,"primaryCompletion":730,"completion":731,"start":732,"enrollment":692,"conditions":733,"interventions":736},"NCT06348147","Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation",[89],"2027-05","2029-05","2026-07",[734,722,735],"Newly Diagnosed Multiple Myeloma","Autologous Stem Cell Transplantation",[737,725,738,662],"Daratumumab","Bortezomib",{"nctId":740,"briefTitle":741,"status":151,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":326,"conditions":746,"interventions":750},"NCT05911321","Isa-Pom-Dex in Elderly\u002FFrail Subjects With RRMM",[89],"2025-06-18","2028-03-26","2023-12-05",[722,167,747,748,749],"Refractory","Aging","Co-morbidity",[724,751,662],"Pomalidomide",{"nctId":649,"briefTitle":650,"status":403,"phases":753,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":754,"interventions":755},[89],[657],[659,65,660,661,461,662,663],{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":100},[],{"trials":761,"activeCount":100},[],{"intervention":41,"totalTrials":264,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":777,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":765,"activeCount":100},[],{"trials":767,"activeCount":9,"soonestReadout":40},[768],{"nctId":38,"briefTitle":39,"status":151,"phases":769,"primaryCompletion":40,"completion":770,"start":771,"enrollment":126,"conditions":772,"interventions":776},[88],"2037-01","2016-06-07",[773,21,774,183,184,185,186,187,775],"Hodgkin Disease","Lymphoma, Non-Hodgkin","Neoplasms by Histologic Type",[41],{"trials":778,"activeCount":9,"soonestReadout":178},[779,783],{"nctId":227,"briefTitle":228,"status":229,"phases":780,"primaryCompletion":178,"completion":231,"start":232,"enrollment":233,"conditions":781,"interventions":782},[89],[235,236],[238,239,95],{"nctId":784,"briefTitle":785,"status":151,"phases":786,"primaryCompletion":178,"completion":179,"start":787,"enrollment":788,"conditions":789,"interventions":790},"NCT02690545","Study of CD30 CAR for Relapsed\u002FRefractory CD30+ HL and CD30+ NHL",[88,89],"2016-08-26",38,[21,774,183,184,185,186,187,775],[41],{"trials":792,"activeCount":100},[],{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"intervention":46,"totalTrials":264,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":816,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":800,"activeCount":100},[],{"trials":802,"activeCount":100},[803],{"nctId":804,"briefTitle":805,"status":403,"phases":806,"primaryCompletion":807,"completion":808,"start":809,"enrollment":9,"conditions":810,"interventions":812},"NCT05911308","Abequolixron (RGX-104) and Durvalumab in Lung Cancer",[88],"2024-10-04","2025-02-27","2024-04-01",[811],"Non-Small Cell Lung Cancer",[46,645,813,814,815],"Abequolixron","Abraxane","Pemetrexed",{"trials":817,"activeCount":233,"soonestReadout":45},[818,827],{"nctId":58,"briefTitle":59,"status":151,"phases":819,"primaryCompletion":60,"completion":820,"start":821,"enrollment":126,"conditions":822,"interventions":826},[89],"2026-05-06","2019-10-07",[823,824,694,825],"Larynx","Lip","Digestive Organs--Diseases",[46],{"nctId":43,"briefTitle":44,"status":151,"phases":828,"primaryCompletion":45,"completion":690,"start":691,"enrollment":692,"conditions":829,"interventions":830},[89],[612,694,695,696,697,632],[46,645,699,461],{"trials":832,"activeCount":100},[],{"trials":834,"activeCount":100},[],{"trials":836,"activeCount":100},[],{"intervention":724,"totalTrials":233,"cells":838},{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":853,"PHASE4":855,"NA":857},{"trials":840,"activeCount":100},[],{"trials":842,"activeCount":100},[],{"trials":844,"activeCount":233,"soonestReadout":743},[845,849],{"nctId":715,"briefTitle":716,"status":106,"phases":846,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":847,"interventions":848},[89],[722,18],[724,725,662],{"nctId":740,"briefTitle":741,"status":151,"phases":850,"primaryCompletion":743,"completion":744,"start":745,"enrollment":326,"conditions":851,"interventions":852},[89],[722,167,747,748,749],[724,751,662],{"trials":854,"activeCount":100},[],{"trials":856,"activeCount":100},[],{"trials":858,"activeCount":100},[],{"intervention":860,"totalTrials":233,"cells":861},"Tirzepatide",{"EARLY_PHASE1":862,"PHASE1":873,"PHASE2":875,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":863,"activeCount":9,"soonestReadout":868},[864],{"nctId":865,"briefTitle":866,"status":106,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":139,"conditions":870,"interventions":872},"NCT07065552","Tirzepatide in Obesity-Driven Endometrial Cancer",[87],"2028-07","2026-04-27",[34,871],"Obesity",[860],{"trials":874,"activeCount":100},[],{"trials":876,"activeCount":9,"soonestReadout":881},[877],{"nctId":878,"briefTitle":879,"status":442,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":336,"conditions":883,"interventions":886},"NCT07078838","Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer",[89],"2029-03","2026-04",[34,884,885],"Endometrial Intraepithelial Neoplasia","Grade 1 Endometrial Endometrioid Carcinoma",[860],{"trials":888,"activeCount":100},[],{"trials":890,"activeCount":100},[],{"trials":892,"activeCount":100},[],{"intervention":449,"totalTrials":233,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":912,"PHASE3":918,"PHASE4":920,"NA":922},{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":9,"soonestReadout":903},[899],{"nctId":900,"briefTitle":901,"status":106,"phases":902,"primaryCompletion":903,"completion":904,"start":905,"enrollment":35,"conditions":906,"interventions":910},"NCT06902376","XL092 and Cemiplimab in BRAF WT Thyroid Cancer",[88],"2028-03-31","2028-08-31","2025-06-03",[907,908,909],"Anaplastic Thyroid Cancer","Thyroid Cancer","BRAF Mutation-Related Tumors",[911,449],"Cemiplimab",{"trials":913,"activeCount":9,"soonestReadout":163},[914],{"nctId":440,"briefTitle":441,"status":442,"phases":915,"primaryCompletion":163,"completion":163,"start":444,"enrollment":445,"conditions":916,"interventions":917},[89],[447,249],[449,56],{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":100},[],{"trials":923,"activeCount":100},[],{"intervention":645,"totalTrials":27,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":946,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":927,"activeCount":100},[],{"trials":929,"activeCount":100},[930,934,942],{"nctId":576,"briefTitle":577,"status":229,"phases":931,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":932,"interventions":933},[88],[584],[371,586,587,588,589],{"nctId":935,"briefTitle":936,"status":229,"phases":937,"primaryCompletion":628,"completion":581,"start":938,"enrollment":939,"conditions":940,"interventions":941},"NCT00520000","Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors",[88],"2004-12",47,[584],[645,814,814,814],{"nctId":804,"briefTitle":805,"status":403,"phases":943,"primaryCompletion":807,"completion":808,"start":809,"enrollment":9,"conditions":944,"interventions":945},[88],[811],[46,645,813,814,815],{"trials":947,"activeCount":9,"soonestReadout":45},[948,958,970,981,990,999,1003,1007,1011,1021,1030,1041],{"nctId":949,"briefTitle":950,"status":229,"phases":951,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":956},"NCT00280735","Ph II Adjuvant Carboplatin\u002FDocetaxel in Curatively Resected Stage I-IIIA NSCLC",[89],"2011-07","2004-05",75,[24],[371,957],"docetaxel",{"nctId":959,"briefTitle":960,"status":229,"phases":961,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":966,"interventions":967},"NCT00280150","Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer",[88,89],"2012-01","2013-01","2006-01",46,[24],[968,371,969,351],"bevacizumab","erlotinib hydrochloride",{"nctId":971,"briefTitle":972,"status":973,"phases":974,"primaryCompletion":975,"completion":975,"start":976,"enrollment":100,"conditions":977,"interventions":978},"NCT00998101","Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy","WITHDRAWN",[89],"2009-11","2009-07",[24],[979,371,980],"cetuximab","ixabepilone",{"nctId":982,"briefTitle":983,"status":229,"phases":984,"primaryCompletion":985,"completion":985,"start":986,"enrollment":30,"conditions":987,"interventions":988},"NCT02124707","Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",[89],"2019-10-01","2014-06-16",[249,643],[989,646,645],"Cetuximab",{"nctId":991,"briefTitle":992,"status":229,"phases":993,"primaryCompletion":994,"completion":995,"start":996,"enrollment":336,"conditions":997,"interventions":998},"NCT01412229","Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck",[89],"2015-06-20","2019-12","2012-02",[249],[989,699,645],{"nctId":636,"briefTitle":637,"status":229,"phases":1000,"primaryCompletion":639,"completion":640,"start":641,"enrollment":336,"conditions":1001,"interventions":1002},[89],[249,643],[645,646,647,461,461],{"nctId":361,"briefTitle":362,"status":229,"phases":1004,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":1005,"interventions":1006},[89],[15],[370,371,172,372,351],{"nctId":43,"briefTitle":44,"status":151,"phases":1008,"primaryCompletion":45,"completion":690,"start":691,"enrollment":692,"conditions":1009,"interventions":1010},[89],[612,694,695,696,697,632],[46,645,699,461],{"nctId":1012,"briefTitle":1013,"status":229,"phases":1014,"primaryCompletion":964,"completion":308,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1018},"NCT00280787","Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim",[89],"2003-11",24,[469],[646,645,1019,1020],"CPT-11","Pegfilgrastim",{"nctId":1022,"briefTitle":1023,"status":229,"phases":1024,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":788,"conditions":1028,"interventions":1029},"NCT01344824","Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light\u002FNever Smokers",[89],"2016-05-24","2016-07-20","2010-03",[24],[968,371,969,588],{"nctId":1031,"briefTitle":1032,"status":403,"phases":1033,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1040},"NCT00454324","Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer",[89],"2010-07","2014-12","2006-04",30,[1039],"Small Cell Lung Cancer",[645,814],{"nctId":1042,"briefTitle":1043,"status":229,"phases":1044,"primaryCompletion":1045,"completion":1046,"start":1047,"enrollment":1048,"conditions":1049,"interventions":1050},"NCT00232505","Cetuximab + \u002F - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer",[89],"2010-06-21","2012-08-12","2005-11",112,[15],[979,371],{"trials":1052,"activeCount":100},[],{"trials":1054,"activeCount":100},[],{"trials":1056,"activeCount":100},[],{"intervention":1058,"totalTrials":655,"cells":1059},"oxaliplatin",{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1103,"PHASE3":1134,"PHASE4":1136,"NA":1138},{"trials":1061,"activeCount":100},[],{"trials":1063,"activeCount":100},[1064,1077,1091],{"nctId":1065,"briefTitle":1066,"status":229,"phases":1067,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT00610948","Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment",[88],"2013-05","2016-01","2008-03",74,[584],[1074,1075,634,1076,1058],"panitumumab","everolimus","leucovorin calcium",{"nctId":1078,"briefTitle":1079,"status":229,"phases":1080,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":549,"conditions":1084,"interventions":1088},"NCT00266097","Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and\u002For Metastatic Pancreatic Cancer or Biliary Tract Cancer",[88],"2009-03","2011-09","2004-08",[1085,1086,1087],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Pancreatic Cancer",[969,1089,1058,1089,1090],"gemcitabine hydrochloride","Oxaliplatin",{"nctId":1092,"briefTitle":1093,"status":229,"phases":1094,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":11,"conditions":1098,"interventions":1101},"NCT01164215","Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy",[88],"2012-11","2013-09","2010-02",[26,1099,1100],"Diarrhea","Neutropenia",[634,1102,1058],"leucovorin",{"trials":1104,"activeCount":9,"soonestReadout":1119},[1105,1115],{"nctId":1106,"briefTitle":1107,"status":229,"phases":1108,"primaryCompletion":1097,"completion":1109,"start":1110,"enrollment":247,"conditions":1111,"interventions":1113},"NCT00483405","Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer",[89],"2010-12","2006-10",[1112],"Liver Cancer",[979,1114,1058],"capecitabine",{"nctId":1116,"briefTitle":1117,"status":106,"phases":1118,"primaryCompletion":1119,"completion":1120,"start":1121,"enrollment":457,"conditions":1122,"interventions":1130},"NCT03977233","Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer",[89],"2027-07","2030-01","2019-06-12",[1123,1124,1125,1126,1127,1128,1129],"Pancreatic Ductal Adenocarcinoma (PDAC)","Cancer of Pancreas","Pancreatic Cancer, Adult","Pancreas Adenocarcinoma","Pancreatic Neoplasms","Pancreatic Cancer Non-resectable","Pancreatic Cancer Resectable",[1090,1131,1132,1133],"Leucovorin","Irinotecan Hydrochloride","5-FU",{"trials":1135,"activeCount":100},[],{"trials":1137,"activeCount":100},[],{"trials":1139,"activeCount":100},[],{"intervention":65,"totalTrials":155,"cells":1141},{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1157,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1143,"activeCount":100},[],{"trials":1145,"activeCount":100},[1146],{"nctId":1147,"briefTitle":1148,"status":229,"phases":1149,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":35,"conditions":1153,"interventions":1154},"NCT00334438","Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma",[88],"2008-10","2011-10","2006-07",[21],[1155,1156],"rituximab","bortezomib",{"trials":1158,"activeCount":9,"soonestReadout":64},[1159,1167,1171],{"nctId":62,"briefTitle":63,"status":151,"phases":1160,"primaryCompletion":64,"completion":1161,"start":1162,"enrollment":27,"conditions":1163,"interventions":1165},[89],"2026-06-07","2021-06-22",[1164],"Multicentric Castleman Disease",[65,1166],"Etoposide",{"nctId":543,"briefTitle":544,"status":229,"phases":1168,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":1169,"interventions":1170},[89],[551,552,553,21],[149,65],{"nctId":649,"briefTitle":650,"status":403,"phases":1172,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":1173,"interventions":1174},[89],[657],[659,65,660,661,461,662,663],{"trials":1176,"activeCount":100},[],{"trials":1178,"activeCount":100},[],{"trials":1180,"activeCount":100},[],{"intervention":434,"totalTrials":264,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1196,"PHASE2":1198,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1184,"activeCount":100},[1185],{"nctId":1186,"briefTitle":1187,"status":403,"phases":1188,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":655,"conditions":1192,"interventions":1195},"NCT03361800","Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC",[87],"2019-09-18","2019-10-11","2018-11-28",[15,1193,1194],"Invasive Breast Cancer","ER-Negative PR-Negative HER2-Negative Breast Cancer",[434],{"trials":1197,"activeCount":100},[],{"trials":1199,"activeCount":9,"soonestReadout":55},[1200,1204],{"nctId":53,"briefTitle":54,"status":151,"phases":1201,"primaryCompletion":55,"completion":430,"start":431,"enrollment":139,"conditions":1202,"interventions":1203},[89],[29],[56,434],{"nctId":507,"briefTitle":508,"status":229,"phases":1205,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":1206,"interventions":1207},[89],[482],[434,56],{"trials":1209,"activeCount":100},[],{"trials":1211,"activeCount":100},[],{"trials":1213,"activeCount":100},[],{"intervention":699,"totalTrials":264,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1241,"PHASE4":1243,"NA":1245},{"trials":1217,"activeCount":100},[],{"trials":1219,"activeCount":100},[],{"trials":1221,"activeCount":9,"soonestReadout":45},[1222,1233,1237],{"nctId":1223,"briefTitle":1224,"status":229,"phases":1225,"primaryCompletion":1226,"completion":1227,"start":1228,"enrollment":165,"conditions":1229,"interventions":1231},"NCT01702844","Single Arm on the Tolerability of Weekly Nab-paclitaxel",[89],"2017-06-23","2019-07-12","2013-06-25",[1230],"Non Small Cell Lung Cancer (NSCLC)",[1232],"Nab-Paclitaxel",{"nctId":991,"briefTitle":992,"status":229,"phases":1234,"primaryCompletion":994,"completion":995,"start":996,"enrollment":336,"conditions":1235,"interventions":1236},[89],[249],[989,699,645],{"nctId":43,"briefTitle":44,"status":151,"phases":1238,"primaryCompletion":45,"completion":690,"start":691,"enrollment":692,"conditions":1239,"interventions":1240},[89],[612,694,695,696,697,632],[46,645,699,461],{"trials":1242,"activeCount":100},[],{"trials":1244,"activeCount":100},[],{"trials":1246,"activeCount":100},[],{"intervention":725,"totalTrials":264,"cells":1248},{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1262,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1250,"activeCount":100},[],{"trials":1252,"activeCount":100},[1253],{"nctId":1254,"briefTitle":1255,"status":229,"phases":1256,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":139,"conditions":1259,"interventions":1261},"NCT01578954","Lenalidomide as Consolidation and Maintenance in Adults >\u002F= 60 Years of Age With AML Following Standard Induction",[88],"2016-05-18","2012-06-28",[1260],"Acute Myeloid Leukemia",[725],{"trials":1263,"activeCount":9,"soonestReadout":718},[1264,1268],{"nctId":715,"briefTitle":716,"status":106,"phases":1265,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":1266,"interventions":1267},[89],[722,18],[724,725,662],{"nctId":727,"briefTitle":728,"status":415,"phases":1269,"primaryCompletion":730,"completion":731,"start":732,"enrollment":692,"conditions":1270,"interventions":1271},[89],[734,722,735],[737,725,738,662],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"trials":1277,"activeCount":100},[],{"intervention":1131,"totalTrials":264,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1288,"PHASE3":1307,"PHASE4":1309,"NA":1311},{"trials":1281,"activeCount":100},[],{"trials":1283,"activeCount":100},[1284],{"nctId":1092,"briefTitle":1093,"status":229,"phases":1285,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":11,"conditions":1286,"interventions":1287},[88],[26,1099,1100],[634,1102,1058],{"trials":1289,"activeCount":9,"soonestReadout":1119},[1290,1303],{"nctId":1291,"briefTitle":1292,"status":229,"phases":1293,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1299},"NCT02138617","Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer",[89],"2024-08-01","2014-05-06",100,[1298],"Colon Cancer",[1300,1131,1301,1302],"5-Fluorouracil","Irinotecan","Bevacizumab",{"nctId":1116,"briefTitle":1117,"status":106,"phases":1304,"primaryCompletion":1119,"completion":1120,"start":1121,"enrollment":457,"conditions":1305,"interventions":1306},[89],[1123,1124,1125,1126,1127,1128,1129],[1090,1131,1132,1133],{"trials":1308,"activeCount":100},[],{"trials":1310,"activeCount":100},[],{"trials":1312,"activeCount":100},[],{"intervention":1314,"totalTrials":264,"cells":1315},"Erlotinib",{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1354,"PHASE4":1356,"NA":1358},{"trials":1317,"activeCount":100},[],{"trials":1319,"activeCount":100},[],{"trials":1321,"activeCount":9,"soonestReadout":1326},[1322,1337,1345],{"nctId":1323,"briefTitle":1324,"status":106,"phases":1325,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1333},"NCT06483555","Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel",[88,89],"2027-08","2025-02-06",104,[1330,1331,1332],"Pancreatic Adenocarcinoma","Metastatic Pancreatic Cancer","Basal Cell Neoplasm",[661,1334,1314,1335,1336],"Nab paclitaxel","NALIRIFOX","Folfirinox",{"nctId":1338,"briefTitle":1339,"status":229,"phases":1340,"primaryCompletion":1341,"completion":1342,"start":628,"enrollment":110,"conditions":1343,"interventions":1344},"NCT00380029","Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer",[89],"2010-08","2014-06",[29],[1314],{"nctId":1346,"briefTitle":1347,"status":229,"phases":1348,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1353},"NCT01573702","Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)",[89],"2019-03-15","2012-12-11",32,[469],[1314],{"trials":1355,"activeCount":100},[],{"trials":1357,"activeCount":100},[],{"trials":1359,"activeCount":100},[],{"intervention":1166,"totalTrials":233,"cells":1361},{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1370,"PHASE3":1376,"PHASE4":1378,"NA":1380},{"trials":1363,"activeCount":100},[],{"trials":1365,"activeCount":100},[1366],{"nctId":576,"briefTitle":577,"status":229,"phases":1367,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":1368,"interventions":1369},[88],[584],[371,586,587,588,589],{"trials":1371,"activeCount":9,"soonestReadout":64},[1372],{"nctId":62,"briefTitle":63,"status":151,"phases":1373,"primaryCompletion":64,"completion":1161,"start":1162,"enrollment":27,"conditions":1374,"interventions":1375},[89],[1164],[65,1166],{"trials":1377,"activeCount":100},[],{"trials":1379,"activeCount":100},[],{"trials":1381,"activeCount":100},[],{"intervention":1383,"totalTrials":233,"cells":1384},"Memantine",{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1417,"PHASE4":1419,"NA":1421},{"trials":1386,"activeCount":100},[],{"trials":1388,"activeCount":100},[],{"trials":1390,"activeCount":9,"soonestReadout":1395},[1391,1407],{"nctId":1392,"briefTitle":1393,"status":106,"phases":1394,"primaryCompletion":1395,"completion":1395,"start":1396,"enrollment":1397,"conditions":1398,"interventions":1406},"NCT06727773","Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer",[89],"2029-06-15","2025-08-19",90,[15,1399,1400,1401,1402,1403,1404,1405],"Locally Advanced Breast Cancer","Cognitive Impairment","Cognitive Decline","Cognitive Change","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III",[1383],{"nctId":1408,"briefTitle":1409,"status":229,"phases":1410,"primaryCompletion":1411,"completion":1411,"start":1412,"enrollment":1413,"conditions":1414,"interventions":1416},"NCT04033419","Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer",[89],"2022-04-04","2019-09-25",55,[1401,1415],"Chemo-brain",[1383],{"trials":1418,"activeCount":100},[],{"trials":1420,"activeCount":100},[],{"trials":1422,"activeCount":100},[],{"intervention":1424,"totalTrials":233,"cells":1425},"FOLFIRINOX",{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1427,"activeCount":100},[],{"trials":1429,"activeCount":100},[],{"trials":1431,"activeCount":9,"soonestReadout":1326},[1432,1441],{"nctId":1433,"briefTitle":1434,"status":403,"phases":1435,"primaryCompletion":1436,"completion":1437,"start":962,"enrollment":1438,"conditions":1439,"interventions":1440},"NCT01688336","FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer",[89],"2016-08-22","2016-11-22",9,[1087],[1424],{"nctId":1323,"briefTitle":1324,"status":106,"phases":1442,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1328,"conditions":1443,"interventions":1444},[88,89],[1330,1331,1332],[661,1334,1314,1335,1336],{"trials":1446,"activeCount":100},[],{"trials":1448,"activeCount":100},[],{"trials":1450,"activeCount":100},[],{"intervention":661,"totalTrials":233,"cells":1452},{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1454,"activeCount":100},[],{"trials":1456,"activeCount":100},[],{"trials":1458,"activeCount":9,"soonestReadout":1326},[1459,1463],{"nctId":1323,"briefTitle":1324,"status":106,"phases":1460,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1328,"conditions":1461,"interventions":1462},[88,89],[1330,1331,1332],[661,1334,1314,1335,1336],{"nctId":649,"briefTitle":650,"status":403,"phases":1464,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":1465,"interventions":1466},[89],[657],[659,65,660,661,461,662,663],{"trials":1468,"activeCount":100},[],{"trials":1470,"activeCount":100},[],{"trials":1472,"activeCount":100},[],{"intervention":1474,"totalTrials":9,"cells":1475},"5% 5-fluorouracil Topical Cream",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":9,"soonestReadout":1486},[1482],{"nctId":1483,"briefTitle":1484,"status":442,"phases":1485,"primaryCompletion":1486,"completion":1487,"start":732,"enrollment":1488,"conditions":1489,"interventions":1500},"NCT07545746","Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya",[89],"2027-09","2028-03",140,[1490,1491,1492,1493,1494,1495,1496,1497,1498,1499],"HIV Infections","HPV Infection","Cervix Cancer","CIN2","CIN3","CIN1","CIN","Cervical Intraepithelial Neoplasia Grade 3","Cervical Intraepithelial Neoplasia Grade 1","Cervical Intraepithelial Neoplasia Grade 2\u002F3",[1474],{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":100},[],{"intervention":1508,"totalTrials":9,"cells":1509},"tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene",{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1511,"activeCount":100},[],{"trials":1513,"activeCount":100},[],{"trials":1515,"activeCount":9,"soonestReadout":1520},[1516],{"nctId":1517,"briefTitle":1518,"status":106,"phases":1519,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1397,"conditions":1523,"interventions":1525},"NCT05472792","Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy",[89],"2027-04-15","2032-04-15","2022-05-17",[15,1524],"Quality of Life",[1508],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[],{"intervention":1533,"totalTrials":9,"cells":1534},"Trilaciclib",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1536,"activeCount":100},[],{"trials":1538,"activeCount":100},[],{"trials":1540,"activeCount":9,"soonestReadout":1545},[1541],{"nctId":1542,"briefTitle":1543,"status":106,"phases":1544,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":1037,"conditions":1548,"interventions":1550},"NCT05578326","Study of Trilaciclib and Lurbinectidin",[89],"2026-12-25","2028-12-25","2022-10-12",[24,1549],"Small-cell Lung Cancer",[1533,1551],"Lurbinectedin",{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":100},[],{"trials":1557,"activeCount":100},[],{"intervention":1551,"totalTrials":9,"cells":1559},{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":9,"soonestReadout":1545},[1566],{"nctId":1542,"briefTitle":1543,"status":106,"phases":1567,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":1037,"conditions":1568,"interventions":1569},[89],[24,1549],[1533,1551],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[],{"intervention":225,"totalTrials":9,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1588,"PHASE4":1590,"NA":1592},{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":9,"soonestReadout":218},[1584],{"nctId":215,"briefTitle":216,"status":151,"phases":1585,"primaryCompletion":218,"completion":219,"start":220,"enrollment":22,"conditions":1586,"interventions":1587},[88,89],[222,183,184],[224,225,118,95],{"trials":1589,"activeCount":100},[],{"trials":1591,"activeCount":100},[],{"trials":1593,"activeCount":100},[],{"intervention":1334,"totalTrials":9,"cells":1595},{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1597,"activeCount":100},[],{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":9,"soonestReadout":1326},[1602],{"nctId":1323,"briefTitle":1324,"status":106,"phases":1603,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1328,"conditions":1604,"interventions":1605},[88,89],[1330,1331,1332],[661,1334,1314,1335,1336],{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[],{"trials":1611,"activeCount":100},[],{"intervention":1335,"totalTrials":9,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1615,"activeCount":100},[],{"trials":1617,"activeCount":100},[],{"trials":1619,"activeCount":9,"soonestReadout":1326},[1620],{"nctId":1323,"briefTitle":1324,"status":106,"phases":1621,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1328,"conditions":1622,"interventions":1623},[88,89],[1330,1331,1332],[661,1334,1314,1335,1336],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[],{"intervention":751,"totalTrials":9,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1642,"PHASE4":1644,"NA":1646},{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[],{"trials":1637,"activeCount":9,"soonestReadout":743},[1638],{"nctId":740,"briefTitle":741,"status":151,"phases":1639,"primaryCompletion":743,"completion":744,"start":745,"enrollment":326,"conditions":1640,"interventions":1641},[89],[722,167,747,748,749],[724,751,662],{"trials":1643,"activeCount":100},[],{"trials":1645,"activeCount":100},[],{"trials":1647,"activeCount":100},[],{"intervention":85,"totalTrials":9,"cells":1649},{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[],{"trials":1655,"activeCount":9,"soonestReadout":84},[1656],{"nctId":82,"briefTitle":83,"status":151,"phases":1657,"primaryCompletion":84,"completion":1658,"start":1659,"enrollment":395,"conditions":1660,"interventions":1662},[89],"2030-03-14","2020-10-15",[1661],"Central Nervous System Lymphoma",[85],{"trials":1664,"activeCount":100},[],{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[],{"intervention":1670,"totalTrials":9,"cells":1671},"Short Chain Fatty Acid",{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1690,"PHASE4":1692,"NA":1694},{"trials":1673,"activeCount":100},[],{"trials":1675,"activeCount":100},[],{"trials":1677,"activeCount":9,"soonestReadout":1682},[1678],{"nctId":1679,"briefTitle":1680,"status":106,"phases":1681,"primaryCompletion":1682,"completion":1683,"start":50,"enrollment":1684,"conditions":1685,"interventions":1688},"NCT04700527","The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study",[88,89],"2026-04-21","2030-05",122,[1686,1687],"Toxicity","Radiation Toxicity",[1670,1689],"Tapioca Flour",{"trials":1691,"activeCount":100},[],{"trials":1693,"activeCount":100},[],{"trials":1695,"activeCount":100},[],{"intervention":1689,"totalTrials":9,"cells":1697},{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":100},[],{"trials":1703,"activeCount":9,"soonestReadout":1682},[1704],{"nctId":1679,"briefTitle":1680,"status":106,"phases":1705,"primaryCompletion":1682,"completion":1683,"start":50,"enrollment":1684,"conditions":1706,"interventions":1707},[88,89],[1686,1687],[1670,1689],{"trials":1709,"activeCount":100},[],{"trials":1711,"activeCount":100},[],{"trials":1713,"activeCount":100},[],{"intervention":252,"totalTrials":9,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":9,"soonestReadout":244},[1722],{"nctId":241,"briefTitle":242,"status":106,"phases":1723,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":1724,"interventions":1725},[88,89],[249,167,115,250],[118,95,252],{"trials":1727,"activeCount":100},[],{"trials":1729,"activeCount":100},[],{"trials":1731,"activeCount":100},[],{"intervention":1733,"totalTrials":9,"cells":1734},"SERD* + abemaciclib",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1757,"PHASE4":1759,"NA":1761},{"trials":1736,"activeCount":100},[],{"trials":1738,"activeCount":100},[],{"trials":1740,"activeCount":9,"soonestReadout":1745},[1741],{"nctId":1742,"briefTitle":1743,"status":106,"phases":1744,"primaryCompletion":1745,"completion":1745,"start":1746,"enrollment":1747,"conditions":1748,"interventions":1752},"NCT07340541","Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies",[89],"2031-06-02","2026-02-16",700,[15,1749,169,1750,1751],"Metastatic Breast Cancer","Estrogen-receptor-positive Breast Cancer","Hormone Receptor Negative Breast Carcinoma",[1733,1753,1754,1755,1756],"SERD* + everolimus","SERD* + everolimus or capecitabine","SOC","Antiandrogen",{"trials":1758,"activeCount":100},[],{"trials":1760,"activeCount":100},[],{"trials":1762,"activeCount":100},[],{"intervention":1753,"totalTrials":9,"cells":1764},{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1775,"PHASE4":1777,"NA":1779},{"trials":1766,"activeCount":100},[],{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":9,"soonestReadout":1745},[1771],{"nctId":1742,"briefTitle":1743,"status":106,"phases":1772,"primaryCompletion":1745,"completion":1745,"start":1746,"enrollment":1747,"conditions":1773,"interventions":1774},[89],[15,1749,169,1750,1751],[1733,1753,1754,1755,1756],{"trials":1776,"activeCount":100},[],{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[],{"intervention":1754,"totalTrials":9,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1787,"PHASE3":1793,"PHASE4":1795,"NA":1797},{"trials":1784,"activeCount":100},[],{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":9,"soonestReadout":1745},[1789],{"nctId":1742,"briefTitle":1743,"status":106,"phases":1790,"primaryCompletion":1745,"completion":1745,"start":1746,"enrollment":1747,"conditions":1791,"interventions":1792},[89],[15,1749,169,1750,1751],[1733,1753,1754,1755,1756],{"trials":1794,"activeCount":100},[],{"trials":1796,"activeCount":100},[],{"trials":1798,"activeCount":100},[],{"intervention":1755,"totalTrials":9,"cells":1800},{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":9,"soonestReadout":1745},[1807],{"nctId":1742,"briefTitle":1743,"status":106,"phases":1808,"primaryCompletion":1745,"completion":1745,"start":1746,"enrollment":1747,"conditions":1809,"interventions":1810},[89],[15,1749,169,1750,1751],[1733,1753,1754,1755,1756],{"trials":1812,"activeCount":100},[],{"trials":1814,"activeCount":100},[],{"trials":1816,"activeCount":100},[],{"intervention":1756,"totalTrials":9,"cells":1818},{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1829,"PHASE4":1831,"NA":1833},{"trials":1820,"activeCount":100},[],{"trials":1822,"activeCount":100},[],{"trials":1824,"activeCount":9,"soonestReadout":1745},[1825],{"nctId":1742,"briefTitle":1743,"status":106,"phases":1826,"primaryCompletion":1745,"completion":1745,"start":1746,"enrollment":1747,"conditions":1827,"interventions":1828},[89],[15,1749,169,1750,1751],[1733,1753,1754,1755,1756],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[],{"trials":1834,"activeCount":100},[],{"intervention":460,"totalTrials":9,"cells":1836},{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1841,"PHASE3":1847,"PHASE4":1849,"NA":1851},{"trials":1838,"activeCount":100},[],{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":9,"soonestReadout":454},[1843],{"nctId":451,"briefTitle":452,"status":151,"phases":1844,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":1845,"interventions":1846},[89],[423],[56,460,461],{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"intervention":263,"totalTrials":9,"cells":1854},{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1856,"activeCount":100},[],{"trials":1858,"activeCount":100},[],{"trials":1860,"activeCount":9,"soonestReadout":257},[1861],{"nctId":254,"briefTitle":255,"status":106,"phases":1862,"primaryCompletion":257,"completion":258,"start":259,"enrollment":139,"conditions":1863,"interventions":1864},[89],[261],[263,149,95,118],{"trials":1866,"activeCount":100},[],{"trials":1868,"activeCount":100},[],{"trials":1870,"activeCount":100},[],{"intervention":1872,"totalTrials":9,"cells":1873},"Neoadjuvant Pembrolizumab",{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1875,"activeCount":100},[],{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":9,"soonestReadout":1884},[1880],{"nctId":1881,"briefTitle":1882,"status":106,"phases":1883,"primaryCompletion":1884,"completion":1885,"start":1886,"enrollment":1351,"conditions":1887,"interventions":1891},"NCT07276880","Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer",[89],"2027-11","2032-01","2026-03-17",[15,1888,1889,1890],"Triple Negative Breast Cancer (TNBC)","HER2-Negative Breast Carcinoma","Node-positive Breast Cancer",[1872],{"trials":1893,"activeCount":100},[],{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":100},[],{"intervention":1899,"totalTrials":9,"cells":1900},"Azacitidine",{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1905,"PHASE3":1917,"PHASE4":1919,"NA":1921},{"trials":1902,"activeCount":100},[],{"trials":1904,"activeCount":100},[],{"trials":1906,"activeCount":9,"soonestReadout":868},[1907],{"nctId":1908,"briefTitle":1909,"status":442,"phases":1910,"primaryCompletion":868,"completion":868,"start":732,"enrollment":1911,"conditions":1912,"interventions":1914},"NCT07605949","Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML",[89],88,[1913],"Leukemia Acute Myeloid",[1899,1915,1916],"Venetoclax","Revumenib",{"trials":1918,"activeCount":100},[],{"trials":1920,"activeCount":100},[],{"trials":1922,"activeCount":100},[],{"intervention":1915,"totalTrials":9,"cells":1924},{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1926,"activeCount":100},[],{"trials":1928,"activeCount":100},[],{"trials":1930,"activeCount":9,"soonestReadout":868},[1931],{"nctId":1908,"briefTitle":1909,"status":442,"phases":1932,"primaryCompletion":868,"completion":868,"start":732,"enrollment":1911,"conditions":1933,"interventions":1934},[89],[1913],[1899,1915,1916],{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[],{"intervention":1916,"totalTrials":9,"cells":1942},{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1944,"activeCount":100},[],{"trials":1946,"activeCount":100},[],{"trials":1948,"activeCount":9,"soonestReadout":868},[1949],{"nctId":1908,"briefTitle":1909,"status":442,"phases":1950,"primaryCompletion":868,"completion":868,"start":732,"enrollment":1911,"conditions":1951,"interventions":1952},[89],[1913],[1899,1915,1916],{"trials":1954,"activeCount":100},[],{"trials":1956,"activeCount":100},[],{"trials":1958,"activeCount":100},[],{"intervention":1960,"totalTrials":9,"cells":1961},"CHEP",{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1963,"activeCount":100},[],{"trials":1965,"activeCount":100},[],{"trials":1967,"activeCount":9,"soonestReadout":50},[1968],{"nctId":48,"briefTitle":49,"status":151,"phases":1969,"primaryCompletion":50,"completion":1970,"start":1971,"enrollment":1972,"conditions":1973,"interventions":1975},[89],"2028-12-15","2018-10-11",16,[21,1974,185],"Adult T-Cell Leukemia\u002FLymphoma",[51,1960],{"trials":1977,"activeCount":100},[],{"trials":1979,"activeCount":100},[],{"trials":1981,"activeCount":100},[],{"intervention":1132,"totalTrials":9,"cells":1983},{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":100},[],{"trials":1989,"activeCount":9,"soonestReadout":1119},[1990],{"nctId":1116,"briefTitle":1117,"status":106,"phases":1991,"primaryCompletion":1119,"completion":1120,"start":1121,"enrollment":457,"conditions":1992,"interventions":1993},[89],[1123,1124,1125,1126,1127,1128,1129],[1090,1131,1132,1133],{"trials":1995,"activeCount":100},[],{"trials":1997,"activeCount":100},[],{"trials":1999,"activeCount":100},[],{"intervention":1133,"totalTrials":9,"cells":2001},{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":2003,"activeCount":100},[],{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":9,"soonestReadout":1119},[2008],{"nctId":1116,"briefTitle":1117,"status":106,"phases":2009,"primaryCompletion":1119,"completion":1120,"start":1121,"enrollment":457,"conditions":2010,"interventions":2011},[89],[1123,1124,1125,1126,1127,1128,1129],[1090,1131,1132,1133],{"trials":2013,"activeCount":100},[],{"trials":2015,"activeCount":100},[],{"trials":2017,"activeCount":100},[],{"intervention":2019,"totalTrials":9,"cells":2020},"contrast agent perflutren lipid",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2037,"PHASE4":2039,"NA":2041},{"trials":2022,"activeCount":100},[],{"trials":2024,"activeCount":100},[],{"trials":2026,"activeCount":9,"soonestReadout":2031},[2027],{"nctId":2028,"briefTitle":2029,"status":106,"phases":2030,"primaryCompletion":2031,"completion":2031,"start":2032,"enrollment":336,"conditions":2033,"interventions":2036},"NCT07225114","Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging",[89],"2028-12","2025-11-04",[15,2034,2035],"Kidney Neoplasms","Liver Neoplasms",[2019],{"trials":2038,"activeCount":100},[],{"trials":2040,"activeCount":100},[],{"trials":2042,"activeCount":100},[],{"intervention":2044,"totalTrials":9,"cells":2045},"Chemotherapy",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2063,"PHASE4":2065,"NA":2067},{"trials":2047,"activeCount":100},[],{"trials":2049,"activeCount":100},[],{"trials":2051,"activeCount":9,"soonestReadout":2056},[2052],{"nctId":2053,"briefTitle":2054,"status":106,"phases":2055,"primaryCompletion":2056,"completion":2057,"start":2058,"enrollment":582,"conditions":2059,"interventions":2061},"NCT06090864","ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells",[88,89],"2026-07-01","2031-07-01","2024-04-25",[2060,167,747],"Hodgkin Lymphoma",[2044,2062],"Cell",{"trials":2064,"activeCount":100},[],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":100},[],{"intervention":2062,"totalTrials":9,"cells":2070},{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":9,"soonestReadout":2056},[2077],{"nctId":2053,"briefTitle":2054,"status":106,"phases":2078,"primaryCompletion":2056,"completion":2057,"start":2058,"enrollment":582,"conditions":2079,"interventions":2080},[88,89],[2060,167,747],[2044,2062],{"trials":2082,"activeCount":100},[],{"trials":2084,"activeCount":100},[],{"trials":2086,"activeCount":100},[],{"intervention":2088,"totalTrials":9,"cells":2089},"Datopotamab deruxtecan",{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2094,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2091,"activeCount":100},[],{"trials":2093,"activeCount":100},[],{"trials":2095,"activeCount":9,"soonestReadout":2100},[2096],{"nctId":2097,"briefTitle":2098,"status":106,"phases":2099,"primaryCompletion":2100,"completion":2101,"start":2102,"enrollment":2103,"conditions":2104,"interventions":2107},"NCT07069595","PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease",[89],"2031-11-01","2032-11-01","2026-02-26",78,[15,2105,1888,2106],"Residual Disease","Stage II\u002FIII",[2088],{"trials":2109,"activeCount":100},[],{"trials":2111,"activeCount":100},[],{"trials":2113,"activeCount":100},[],{"intervention":224,"totalTrials":233,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2126,"PHASE4":2128,"NA":2130},{"trials":2117,"activeCount":100},[],{"trials":2119,"activeCount":100},[],{"trials":2121,"activeCount":9,"soonestReadout":218},[2122],{"nctId":215,"briefTitle":216,"status":151,"phases":2123,"primaryCompletion":218,"completion":219,"start":220,"enrollment":22,"conditions":2124,"interventions":2125},[88,89],[222,183,184],[224,225,118,95],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"trials":2131,"activeCount":100},[2132],{"nctId":281,"briefTitle":282,"status":274,"phases":2133,"conditions":2134,"interventions":2135},[],[222,183,184],[224,210,118,95],{"intervention":2137,"totalTrials":233,"cells":2138},"Brentuximab vedotin",{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2149,"PHASE4":2151,"NA":2153},{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[],{"trials":2144,"activeCount":9,"soonestReadout":50},[2145],{"nctId":48,"briefTitle":49,"status":151,"phases":2146,"primaryCompletion":50,"completion":1970,"start":1971,"enrollment":1972,"conditions":2147,"interventions":2148},[89],[21,1974,185],[51,1960],{"trials":2150,"activeCount":100},[],{"trials":2152,"activeCount":100},[],{"trials":2154,"activeCount":100},[2155],{"nctId":2156,"briefTitle":2157,"status":229,"phases":2158,"primaryCompletion":2159,"completion":2160,"start":2161,"enrollment":2162,"conditions":2163,"interventions":2164},"NCT01578967","Induction Chemo w\u002FABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I\u002FII Hodgkin Lymphoma",[92],"2016-08-10","2020-12-11","2012-04",41,[277],[2137,2165],"ABVD",{"intervention":2167,"totalTrials":264,"cells":2168},"Palbociclib",{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2184,"PHASE3":2209,"PHASE4":2211,"NA":2213},{"trials":2170,"activeCount":100},[],{"trials":2172,"activeCount":9,"soonestReadout":2177},[2173],{"nctId":2174,"briefTitle":2175,"status":106,"phases":2176,"primaryCompletion":2177,"completion":2178,"start":2179,"enrollment":457,"conditions":2180,"interventions":2182},"NCT03454035","Ulixertinib\u002FPalbociclib in Patients With Advanced Pancreatic and Other Solid Tumors",[88],"2026-07-15","2026-11-24","2018-01-30",[2181,1087,482],"Tumor, Solid",[2183,2167],"Ulixertinib",{"trials":2185,"activeCount":100},[2186,2196],{"nctId":2187,"briefTitle":2188,"status":403,"phases":2189,"primaryCompletion":2190,"completion":2191,"start":2192,"enrollment":35,"conditions":2193,"interventions":2195},"NCT02334527","Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy",[89],"2016-12-02","2017-09-28","2015-03-17",[2194],"Metastatic Urothelial Carcinoma (UC)",[2167],{"nctId":2197,"briefTitle":2198,"status":229,"phases":2199,"primaryCompletion":2200,"completion":2201,"start":2202,"enrollment":1016,"conditions":2203,"interventions":2208},"NCT03446157","Palbociclib and Cetuximab in Metastatic Colorectal Cancer",[89],"2023-05-29","2026-01-26","2018-03-23",[2204,1298,2205,2206,2207],"Cancer of the Colon","Colon Neoplasms","Colonic Cancer","Neoplasms, Colonic",[989,2167],{"trials":2210,"activeCount":100},[],{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[],{"intervention":2183,"totalTrials":9,"cells":2216},{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2218,"activeCount":100},[],{"trials":2220,"activeCount":9,"soonestReadout":2177},[2221],{"nctId":2174,"briefTitle":2175,"status":106,"phases":2222,"primaryCompletion":2177,"completion":2178,"start":2179,"enrollment":457,"conditions":2223,"interventions":2224},[88],[2181,1087,482],[2183,2167],{"trials":2226,"activeCount":100},[],{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":100},[],{"trials":2232,"activeCount":100},[],{"intervention":70,"totalTrials":9,"cells":2234},{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2245,"PHASE3":2247,"PHASE4":2249,"NA":2251},{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":9,"soonestReadout":69},[2239],{"nctId":67,"briefTitle":68,"status":151,"phases":2240,"primaryCompletion":69,"completion":2241,"start":2242,"enrollment":478,"conditions":2243,"interventions":2244},[88],"2039-08-18","2019-01-14",[722,183],[70],{"trials":2246,"activeCount":100},[],{"trials":2248,"activeCount":100},[],{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"intervention":117,"totalTrials":9,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2263,"PHASE3":2265,"PHASE4":2267,"NA":2269},{"trials":2256,"activeCount":100},[],{"trials":2258,"activeCount":9,"soonestReadout":108},[2259],{"nctId":104,"briefTitle":105,"status":106,"phases":2260,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":2261,"interventions":2262},[88],[112,113,114,115],[117,118,95],{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[],{"trials":2268,"activeCount":100},[],{"trials":2270,"activeCount":100},[],{"intervention":131,"totalTrials":9,"cells":2272},{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2281,"PHASE3":2283,"PHASE4":2285,"NA":2287},{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":9,"soonestReadout":123},[2277],{"nctId":120,"briefTitle":121,"status":106,"phases":2278,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":2279,"interventions":2280},[88],[128,129],[131,118,95],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"trials":2286,"activeCount":100},[],{"trials":2288,"activeCount":100},[],{"intervention":148,"totalTrials":9,"cells":2290},{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2299,"PHASE3":2301,"PHASE4":2303,"NA":2305},{"trials":2292,"activeCount":100},[],{"trials":2294,"activeCount":9,"soonestReadout":136},[2295],{"nctId":133,"briefTitle":134,"status":106,"phases":2296,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":2297,"interventions":2298},[88],[141,142,143,144,145,146],[148,95,118,149],{"trials":2300,"activeCount":100},[],{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[],{"trials":2306,"activeCount":100},[],{"intervention":2308,"totalTrials":9,"cells":2309},"CAR.B7-H3T cells",{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2311,"activeCount":100},[],{"trials":2313,"activeCount":9,"soonestReadout":2318},[2314],{"nctId":2315,"briefTitle":2316,"status":106,"phases":2317,"primaryCompletion":2318,"completion":2318,"start":456,"enrollment":2319,"conditions":2320,"interventions":2322},"NCT05366179","Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc",[88],"2030-05-30",36,[2321],"Glioblastoma Multiforme",[2308],{"trials":2324,"activeCount":100},[],{"trials":2326,"activeCount":100},[],{"trials":2328,"activeCount":100},[],{"trials":2330,"activeCount":100},[],{"intervention":2332,"totalTrials":9,"cells":2333},"iC9-CAR.B7-H3 T cell",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2348,"PHASE3":2350,"PHASE4":2352,"NA":2354},{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":9,"soonestReadout":2342},[2338],{"nctId":2339,"briefTitle":2340,"status":106,"phases":2341,"primaryCompletion":2342,"completion":2343,"start":2344,"enrollment":110,"conditions":2345,"interventions":2347},"NCT06158139","Autologous CAR-T Cells Targeting B7-H3 in PDAC",[88],"2028-04","2030-04","2024-07-18",[2346,167,168],"Pancreas Cancer",[2332],{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[],{"trials":2355,"activeCount":100},[],{"intervention":911,"totalTrials":9,"cells":2357},{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2366,"PHASE3":2368,"PHASE4":2370,"NA":2372},{"trials":2359,"activeCount":100},[],{"trials":2361,"activeCount":9,"soonestReadout":903},[2362],{"nctId":900,"briefTitle":901,"status":106,"phases":2363,"primaryCompletion":903,"completion":904,"start":905,"enrollment":35,"conditions":2364,"interventions":2365},[88],[907,908,909],[911,449],{"trials":2367,"activeCount":100},[],{"trials":2369,"activeCount":100},[],{"trials":2371,"activeCount":100},[],{"trials":2373,"activeCount":100},[],{"intervention":75,"totalTrials":9,"cells":2375},{"EARLY_PHASE1":2376,"PHASE1":2378,"PHASE2":2384,"PHASE3":2386,"PHASE4":2388,"NA":2390},{"trials":2377,"activeCount":100},[],{"trials":2379,"activeCount":9,"soonestReadout":74},[2380],{"nctId":72,"briefTitle":73,"status":151,"phases":2381,"primaryCompletion":74,"completion":153,"start":154,"enrollment":155,"conditions":2382,"interventions":2383},[88],[114],[75,95,118],{"trials":2385,"activeCount":100},[],{"trials":2387,"activeCount":100},[],{"trials":2389,"activeCount":100},[],{"trials":2391,"activeCount":100},[],{"intervention":171,"totalTrials":9,"cells":2393},{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2402,"PHASE3":2404,"PHASE4":2406,"NA":2408},{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":9,"soonestReadout":162},[2398],{"nctId":159,"briefTitle":160,"status":106,"phases":2399,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":2400,"interventions":2401},[88],[15,167,168,169],[171,172,173],{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"trials":2409,"activeCount":100},[],{"intervention":196,"totalTrials":9,"cells":2411},{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2420,"PHASE3":2422,"PHASE4":2424,"NA":2426},{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":9,"soonestReadout":178},[2416],{"nctId":175,"briefTitle":176,"status":151,"phases":2417,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":2418,"interventions":2419},[88],[21,183,184,185,186,187,188,189,190,191,192,193,194],[196,197,149,95],{"trials":2421,"activeCount":100},[],{"trials":2423,"activeCount":100},[],{"trials":2425,"activeCount":100},[],{"trials":2427,"activeCount":100},[],{"intervention":197,"totalTrials":9,"cells":2429},{"EARLY_PHASE1":2430,"PHASE1":2432,"PHASE2":2438,"PHASE3":2440,"PHASE4":2442,"NA":2444},{"trials":2431,"activeCount":100},[],{"trials":2433,"activeCount":9,"soonestReadout":178},[2434],{"nctId":175,"briefTitle":176,"status":151,"phases":2435,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":2436,"interventions":2437},[88],[21,183,184,185,186,187,188,189,190,191,192,193,194],[196,197,149,95],{"trials":2439,"activeCount":100},[],{"trials":2441,"activeCount":100},[],{"trials":2443,"activeCount":100},[],{"trials":2445,"activeCount":100},[],{"intervention":209,"totalTrials":9,"cells":2447},{"EARLY_PHASE1":2448,"PHASE1":2450,"PHASE2":2456,"PHASE3":2458,"PHASE4":2460,"NA":2462},{"trials":2449,"activeCount":100},[],{"trials":2451,"activeCount":9,"soonestReadout":202},[2452],{"nctId":199,"briefTitle":200,"status":151,"phases":2453,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":2454,"interventions":2455},[88],[21,207,183,184,185],[209,149,95,210,118],{"trials":2457,"activeCount":100},[],{"trials":2459,"activeCount":100},[],{"trials":2461,"activeCount":100},[],{"trials":2463,"activeCount":100},[],{"intervention":2465,"totalTrials":9,"cells":2466},"Atezolizumab",{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2488,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2468,"activeCount":100},[],{"trials":2470,"activeCount":9,"soonestReadout":2475},[2471],{"nctId":2472,"briefTitle":2473,"status":106,"phases":2474,"primaryCompletion":2475,"completion":2476,"start":405,"enrollment":2477,"conditions":2478,"interventions":2486},"NCT05542407","ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer",[88],"2028-02-21","2028-07-31",58,[34,2479,2480,2481,2482,2483,2484,2485],"Metastasis","Endometrioid Endometrial Cancer","Carcinosarcoma","Serous Adenocarcinoma of Endometrium (Diagnosis)","Clear Cell Endometrial Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma",[2465,2487],"ONC201",{"trials":2489,"activeCount":100},[],{"trials":2491,"activeCount":100},[],{"trials":2493,"activeCount":100},[],{"trials":2495,"activeCount":100},[],{"intervention":2487,"totalTrials":9,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2506,"PHASE3":2508,"PHASE4":2510,"NA":2512},{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":9,"soonestReadout":2475},[2502],{"nctId":2472,"briefTitle":2473,"status":106,"phases":2503,"primaryCompletion":2475,"completion":2476,"start":405,"enrollment":2477,"conditions":2504,"interventions":2505},[88],[34,2479,2480,2481,2482,2483,2484,2485],[2465,2487],{"trials":2507,"activeCount":100},[],{"trials":2509,"activeCount":100},[],{"trials":2511,"activeCount":100},[],{"trials":2513,"activeCount":100},[],{"intervention":210,"totalTrials":233,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2524,"PHASE3":2526,"PHASE4":2528,"NA":2530},{"trials":2517,"activeCount":100},[],{"trials":2519,"activeCount":9,"soonestReadout":202},[2520],{"nctId":199,"briefTitle":200,"status":151,"phases":2521,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":2522,"interventions":2523},[88],[21,207,183,184,185],[209,149,95,210,118],{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[2532],{"nctId":281,"briefTitle":282,"status":274,"phases":2533,"conditions":2534,"interventions":2535},[],[222,183,184],[224,210,118,95],{"intervention":80,"totalTrials":155,"cells":2537},{"EARLY_PHASE1":2538,"PHASE1":2544,"PHASE2":2546,"PHASE3":2576,"PHASE4":2578,"NA":2580},{"trials":2539,"activeCount":9,"soonestReadout":79},[2540],{"nctId":77,"briefTitle":78,"status":151,"phases":2541,"primaryCompletion":79,"completion":393,"start":394,"enrollment":395,"conditions":2542,"interventions":2543},[87],[397,398],[80,56],{"trials":2545,"activeCount":100},[],{"trials":2547,"activeCount":100},[2548,2560,2572],{"nctId":2549,"briefTitle":2550,"status":229,"phases":2551,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":2555,"conditions":2556,"interventions":2557},"NCT03442569","PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras\u002FNras\u002FBRAF Wild-type MSS Refractory mCRC",[89],"2020-09-21","2024-12-02","2018-03-09",56,[1298],[2558,80,2559],"Panitumumab","Ipilimumab",{"nctId":2561,"briefTitle":2562,"status":403,"phases":2563,"primaryCompletion":2564,"completion":2565,"start":2566,"enrollment":9,"conditions":2567,"interventions":2570},"NCT03597009","A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion",[88,89],"2020-02-07","2020-02-12","2019-03-06",[2568,2569,24],"Malignant Pleural Effusion","Stage IV Metastatic Cancer",[2571,80],"Talimogene laherparepvec",{"nctId":472,"briefTitle":473,"status":229,"phases":2573,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":2574,"interventions":2575},[89],[480,481,482,483,484],[486,56,80],{"trials":2577,"activeCount":100},[],{"trials":2579,"activeCount":100},[],{"trials":2581,"activeCount":100},[],{"intervention":2583,"totalTrials":9,"cells":2584},"Iohexol 350 Mg\u002FmL Injectable Solution",{"EARLY_PHASE1":2585,"PHASE1":2595,"PHASE2":2597,"PHASE3":2599,"PHASE4":2601,"NA":2603},{"trials":2586,"activeCount":9,"soonestReadout":2591},[2587],{"nctId":2588,"briefTitle":2589,"status":106,"phases":2590,"primaryCompletion":2591,"completion":2591,"start":2592,"enrollment":139,"conditions":2593,"interventions":2594},"NCT05754749","Comparison of CE-DBT and MRI in Patients With Known Breast Lesions",[87],"2026-08-22","2023-03-13",[15],[2583],{"trials":2596,"activeCount":100},[],{"trials":2598,"activeCount":100},[],{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":100},[],{"trials":2604,"activeCount":100},[],{"intervention":2606,"totalTrials":9,"cells":2607},"iC9.GD2.CAR.IL-15 T",{"EARLY_PHASE1":2608,"PHASE1":2620,"PHASE2":2622,"PHASE3":2624,"PHASE4":2626,"NA":2628},{"trials":2609,"activeCount":9,"soonestReadout":2614},[2610],{"nctId":2611,"briefTitle":2612,"status":106,"phases":2613,"primaryCompletion":2614,"completion":2615,"start":2616,"enrollment":1016,"conditions":2617,"interventions":2619},"NCT05620342","Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer",[87],"2027-11-24","2029-10-24","2023-06-21",[24,2618,469],"Small Cell Lung Carcinoma",[2606],{"trials":2621,"activeCount":100},[],{"trials":2623,"activeCount":100},[],{"trials":2625,"activeCount":100},[],{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[],{"intervention":2631,"totalTrials":9,"cells":2632},"standard of care chemotherapy",{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2641,"NA":2643},{"trials":2634,"activeCount":100},[],{"trials":2636,"activeCount":100},[],{"trials":2638,"activeCount":100},[],{"trials":2640,"activeCount":100},[],{"trials":2642,"activeCount":100},[],{"trials":2644,"activeCount":9,"soonestReadout":2649},[2645],{"nctId":2646,"briefTitle":2647,"status":151,"phases":2648,"primaryCompletion":2649,"completion":2650,"start":2651,"enrollment":2652,"conditions":2653,"interventions":2656},"NCT06480773","Kaposi Sarcoma Chemotherapy and Research (KS-CARE)",[],"2025-12-31","2026-12-31","2023-04-25",127,[2654,2655],"Kaposi Sarcoma","HIV",[2631],{"intervention":2658,"totalTrials":233,"cells":2659},"Definity",{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2673,"PHASE4":2675,"NA":2686},{"trials":2661,"activeCount":100},[],{"trials":2663,"activeCount":100},[],{"trials":2665,"activeCount":100},[2666],{"nctId":2667,"briefTitle":2668,"status":403,"phases":2669,"primaryCompletion":1294,"completion":1294,"start":2670,"enrollment":110,"conditions":2671,"interventions":2672},"NCT04136912","3-D Super Resolution Ultrasound Microvascular Imaging",[89],"2022-05-26",[15,908],[2658],{"trials":2674,"activeCount":100},[],{"trials":2676,"activeCount":100},[2677],{"nctId":2678,"briefTitle":2679,"status":229,"phases":2680,"primaryCompletion":2681,"completion":2681,"start":2682,"enrollment":139,"conditions":2683,"interventions":2685},"NCT03544268","Academic-Industrial Partnership for Translation of Acoustic Angiography",[91],"2021-05-25","2019-03-25",[2684],"Signs and Symptoms",[2658],{"trials":2687,"activeCount":100},[],{"intervention":2689,"totalTrials":9,"cells":2690},"Olanzapine 5 MG",{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2695,"PHASE3":2697,"PHASE4":2709,"NA":2711},{"trials":2692,"activeCount":100},[],{"trials":2694,"activeCount":100},[],{"trials":2696,"activeCount":100},[],{"trials":2698,"activeCount":100},[2699],{"nctId":2700,"briefTitle":2701,"status":229,"phases":2702,"primaryCompletion":2703,"completion":2703,"start":2704,"enrollment":2705,"conditions":2706,"interventions":2708},"NCT04535141","Olanzapine for Nausea\u002FVomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants",[90],"2022-04-11","2020-08-18",91,[2707],"Chemotherapy-induced Nausea and Vomiting",[2689],{"trials":2710,"activeCount":100},[],{"trials":2712,"activeCount":100},[],{"intervention":351,"totalTrials":2714,"cells":2715},8,{"EARLY_PHASE1":2716,"PHASE1":2718,"PHASE2":2720,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2717,"activeCount":100},[],{"trials":2719,"activeCount":100},[],{"trials":2721,"activeCount":100},[2722,2726,2730,2734,2743,2747,2751,2755],{"nctId":959,"briefTitle":960,"status":229,"phases":2723,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":2724,"interventions":2725},[88,89],[24],[968,371,969,351],{"nctId":982,"briefTitle":983,"status":229,"phases":2727,"primaryCompletion":985,"completion":985,"start":986,"enrollment":30,"conditions":2728,"interventions":2729},[89],[249,643],[989,646,645],{"nctId":625,"briefTitle":626,"status":229,"phases":2731,"primaryCompletion":628,"completion":629,"start":630,"enrollment":445,"conditions":2732,"interventions":2733},[88,89],[632],[586,634,351],{"nctId":2735,"briefTitle":2736,"status":229,"phases":2737,"primaryCompletion":2738,"completion":2739,"start":2740,"conditions":2741,"interventions":2742},"NCT00006108","Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer",[88,89],"2001-09","2002-07","1999-08",[15],[349,1114,351],{"nctId":340,"briefTitle":341,"status":229,"phases":2744,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":2745,"interventions":2746},[89],[15],[349,172,350,351],{"nctId":636,"briefTitle":637,"status":229,"phases":2748,"primaryCompletion":639,"completion":640,"start":641,"enrollment":336,"conditions":2749,"interventions":2750},[89],[249,643],[645,646,647,461,461],{"nctId":361,"briefTitle":362,"status":229,"phases":2752,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":2753,"interventions":2754},[89],[15],[370,371,172,372,351],{"nctId":1012,"briefTitle":1013,"status":229,"phases":2756,"primaryCompletion":964,"completion":308,"start":1015,"enrollment":1016,"conditions":2757,"interventions":2758},[89],[469],[646,645,1019,1020],{"trials":2760,"activeCount":100},[],{"trials":2762,"activeCount":100},[],{"trials":2764,"activeCount":100},[],{"intervention":979,"totalTrials":211,"cells":2766},{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2771,"PHASE3":2806,"PHASE4":2808,"NA":2810},{"trials":2768,"activeCount":100},[],{"trials":2770,"activeCount":100},[],{"trials":2772,"activeCount":100},[2773,2777,2781,2785,2789,2793,2802],{"nctId":971,"briefTitle":972,"status":973,"phases":2774,"primaryCompletion":975,"completion":975,"start":976,"enrollment":100,"conditions":2775,"interventions":2776},[89],[24],[979,371,980],{"nctId":982,"briefTitle":983,"status":229,"phases":2778,"primaryCompletion":985,"completion":985,"start":986,"enrollment":30,"conditions":2779,"interventions":2780},[89],[249,643],[989,646,645],{"nctId":1106,"briefTitle":1107,"status":229,"phases":2782,"primaryCompletion":1097,"completion":1109,"start":1110,"enrollment":247,"conditions":2783,"interventions":2784},[89],[1112],[979,1114,1058],{"nctId":991,"briefTitle":992,"status":229,"phases":2786,"primaryCompletion":994,"completion":995,"start":996,"enrollment":336,"conditions":2787,"interventions":2788},[89],[249],[989,699,645],{"nctId":2197,"briefTitle":2198,"status":229,"phases":2790,"primaryCompletion":2200,"completion":2201,"start":2202,"enrollment":1016,"conditions":2791,"interventions":2792},[89],[2204,1298,2205,2206,2207],[989,2167],{"nctId":2794,"briefTitle":2795,"status":403,"phases":2796,"primaryCompletion":2797,"completion":975,"start":2798,"enrollment":126,"conditions":2799,"interventions":2800},"NCT00519831","Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC",[89],"2008-02","2007-08",[24],[979,2801],"vinflunine",{"nctId":1042,"briefTitle":1043,"status":229,"phases":2803,"primaryCompletion":1045,"completion":1046,"start":1047,"enrollment":1048,"conditions":2804,"interventions":2805},[89],[15],[979,371],{"trials":2807,"activeCount":100},[],{"trials":2809,"activeCount":100},[],{"trials":2811,"activeCount":100},[],{"intervention":349,"totalTrials":211,"cells":2813},{"EARLY_PHASE1":2814,"PHASE1":2828,"PHASE2":2842,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2815,"activeCount":100},[2816],{"nctId":2817,"briefTitle":2818,"status":229,"phases":2819,"primaryCompletion":2820,"completion":2820,"start":2821,"enrollment":445,"conditions":2822,"interventions":2824},"NCT01875666","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",[87],"2016-12-19","2013-08-05",[2823],"Breast Neoplasms",[2825,2826,2827],"Trastuzumab","pertuzumab","lapatinib",{"trials":2829,"activeCount":100},[2830],{"nctId":2831,"briefTitle":2832,"status":229,"phases":2833,"primaryCompletion":2834,"completion":2835,"start":2836,"enrollment":939,"conditions":2837,"interventions":2838},"NCT01300962","Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer",[88],"2017-02-07","2018-12-31","2011-08",[1749],[2839,2840,2841,2825,647],"BMK120","Capecitabine","BYL719",{"trials":2843,"activeCount":100},[2844,2848,2852,2862,2872],{"nctId":2735,"briefTitle":2736,"status":229,"phases":2845,"primaryCompletion":2738,"completion":2739,"start":2740,"conditions":2846,"interventions":2847},[88,89],[15],[349,1114,351],{"nctId":340,"briefTitle":341,"status":229,"phases":2849,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":2850,"interventions":2851},[89],[15],[349,172,350,351],{"nctId":2853,"briefTitle":2854,"status":403,"phases":2855,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":2555,"conditions":2858,"interventions":2859},"NCT00088985","Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer",[89],"2009-10","2004-01",[15],[2860,349,2861],"therapeutic autologous dendritic cells","vinorelbine ditartrate",{"nctId":2863,"briefTitle":2864,"status":229,"phases":2865,"primaryCompletion":2866,"completion":2867,"start":2868,"enrollment":22,"conditions":2869,"interventions":2870},"NCT00266110","Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",[89],"2013-02","2017-10-27","2005-12",[15],[2871,2860,349,2861],"sargramostim",{"nctId":2873,"briefTitle":2874,"status":229,"phases":2875,"primaryCompletion":547,"completion":2876,"start":1082,"enrollment":1351,"conditions":2877,"interventions":2879},"NCT01305941","A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",[89],"2017-10-16",[2878],"HER-2 Positive Breast Cancer",[2880,2881,2825],"Everolimus","Vinorelbine",{"trials":2883,"activeCount":100},[],{"trials":2885,"activeCount":100},[],{"trials":2887,"activeCount":100},[],{"intervention":969,"totalTrials":326,"cells":2889},{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2914,"PHASE3":2934,"PHASE4":2936,"NA":2938},{"trials":2891,"activeCount":100},[],{"trials":2893,"activeCount":100},[2894,2902,2906],{"nctId":2895,"briefTitle":2896,"status":403,"phases":2897,"primaryCompletion":2797,"completion":1070,"start":2898,"enrollment":395,"conditions":2899,"interventions":2901},"NCT00227032","Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme",[88],"2005-09",[2900],"Brain and Central Nervous System Tumors",[969],{"nctId":1078,"briefTitle":1079,"status":229,"phases":2903,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":549,"conditions":2904,"interventions":2905},[88],[1085,1086,1087],[969,1089,1058,1089,1090],{"nctId":2907,"briefTitle":2908,"status":229,"phases":2909,"primaryCompletion":1150,"completion":2910,"start":2911,"enrollment":2162,"conditions":2912,"interventions":2913},"NCT00320073","Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors",[88],"2010-01","2006-08",[584],[969,588,2801],{"trials":2915,"activeCount":100},[2916,2926,2930],{"nctId":2917,"briefTitle":2918,"status":229,"phases":2919,"primaryCompletion":2920,"completion":2921,"start":2922,"enrollment":2923,"conditions":2924,"interventions":2925},"NCT00283244","Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib\u002FElderly Patients W\u002F IIIB\u002FIV NSCLC",[89],"2014-09","2014-10","2006-03",147,[24],[969,1089],{"nctId":959,"briefTitle":960,"status":229,"phases":2927,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":2928,"interventions":2929},[88,89],[24],[968,371,969,351],{"nctId":1022,"briefTitle":1023,"status":229,"phases":2931,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":788,"conditions":2932,"interventions":2933},[89],[24],[968,371,969,588],{"trials":2935,"activeCount":100},[],{"trials":2937,"activeCount":100},[],{"trials":2939,"activeCount":100},[],{"intervention":1156,"totalTrials":655,"cells":2941},{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2969,"PHASE3":2985,"PHASE4":2987,"NA":2989},{"trials":2943,"activeCount":100},[],{"trials":2945,"activeCount":100},[2946,2950,2958],{"nctId":1147,"briefTitle":1148,"status":229,"phases":2947,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":35,"conditions":2948,"interventions":2949},[88],[21],[1155,1156],{"nctId":2951,"briefTitle":2952,"status":229,"phases":2953,"primaryCompletion":2954,"completion":678,"start":2955,"enrollment":513,"conditions":2956,"interventions":2957},"NCT00280176","Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer",[88],"2008-11","2003-04",[26],[1156,634],{"nctId":2959,"briefTitle":2960,"status":403,"phases":2961,"primaryCompletion":2962,"completion":2963,"start":1150,"enrollment":1351,"conditions":2964,"interventions":2966},"NCT00744354","Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma",[88],"2011-12","2015-04",[2965],"Multiple Myeloma and Plasma Cell Neoplasm",[1156,2967,2968],"pegylated liposomal doxorubicin hydrochloride","vorinostat",{"trials":2970,"activeCount":100},[2971,2975],{"nctId":727,"briefTitle":728,"status":415,"phases":2972,"primaryCompletion":730,"completion":731,"start":732,"enrollment":692,"conditions":2973,"interventions":2974},[89],[734,722,735],[737,725,738,662],{"nctId":2976,"briefTitle":2977,"status":973,"phases":2978,"primaryCompletion":2979,"completion":2980,"start":2161,"enrollment":100,"conditions":2981,"interventions":2982},"NCT01492881","Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed\u002FRefractory Multiple Myeloma",[89],"2015-01","2017-01",[722],[2983,738,2984],"Vorinostat","pegylated liposomal doxorubicin",{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[],{"trials":2990,"activeCount":100},[],{"intervention":634,"totalTrials":155,"cells":2992},{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":3009,"PHASE3":3015,"PHASE4":3017,"NA":3019},{"trials":2994,"activeCount":100},[],{"trials":2996,"activeCount":100},[2997,3001,3005],{"nctId":1065,"briefTitle":1066,"status":229,"phases":2998,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":2999,"interventions":3000},[88],[584],[1074,1075,634,1076,1058],{"nctId":2951,"briefTitle":2952,"status":229,"phases":3002,"primaryCompletion":2954,"completion":678,"start":2955,"enrollment":513,"conditions":3003,"interventions":3004},[88],[26],[1156,634],{"nctId":1092,"briefTitle":1093,"status":229,"phases":3006,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":11,"conditions":3007,"interventions":3008},[88],[26,1099,1100],[634,1102,1058],{"trials":3010,"activeCount":100},[3011],{"nctId":625,"briefTitle":626,"status":229,"phases":3012,"primaryCompletion":628,"completion":629,"start":630,"enrollment":445,"conditions":3013,"interventions":3014},[88,89],[632],[586,634,351],{"trials":3016,"activeCount":100},[],{"trials":3018,"activeCount":100},[],{"trials":3020,"activeCount":100},[],{"intervention":588,"totalTrials":155,"cells":3022},{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3035,"PHASE3":3051,"PHASE4":3053,"NA":3055},{"trials":3024,"activeCount":100},[],{"trials":3026,"activeCount":100},[3027,3031],{"nctId":576,"briefTitle":577,"status":229,"phases":3028,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":3029,"interventions":3030},[88],[584],[371,586,587,588,589],{"nctId":2907,"briefTitle":2908,"status":229,"phases":3032,"primaryCompletion":1150,"completion":2910,"start":2911,"enrollment":2162,"conditions":3033,"interventions":3034},[88],[584],[969,588,2801],{"trials":3036,"activeCount":100},[3037,3047],{"nctId":3038,"briefTitle":3039,"status":403,"phases":3040,"primaryCompletion":3041,"completion":3042,"start":3043,"enrollment":395,"conditions":3044,"interventions":3046},"NCT00280748","Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer",[89],"2008-12","2009-04","2005-05",[24,3045],"Metastatic Cancer",[588],{"nctId":1022,"briefTitle":1023,"status":229,"phases":3048,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":788,"conditions":3049,"interventions":3050},[89],[24],[968,371,969,588],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[],{"trials":3056,"activeCount":100},[],{"intervention":2880,"totalTrials":264,"cells":3058},{"EARLY_PHASE1":3059,"PHASE1":3061,"PHASE2":3067,"PHASE3":3082,"PHASE4":3084,"NA":3086},{"trials":3060,"activeCount":100},[],{"trials":3062,"activeCount":100},[3063],{"nctId":1065,"briefTitle":1066,"status":229,"phases":3064,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":3065,"interventions":3066},[88],[584],[1074,1075,634,1076,1058],{"trials":3068,"activeCount":100},[3069,3078],{"nctId":3070,"briefTitle":3071,"status":229,"phases":3072,"primaryCompletion":3073,"completion":3073,"start":2962,"enrollment":1016,"conditions":3074,"interventions":3076},"NCT01488487","Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma",[89],"2015-03",[3075],"Advanced Adult Hepatocellular Carcinoma",[2880,3077],"Pasireotide",{"nctId":2873,"briefTitle":2874,"status":229,"phases":3079,"primaryCompletion":547,"completion":2876,"start":1082,"enrollment":1351,"conditions":3080,"interventions":3081},[89],[2878],[2880,2881,2825],{"trials":3083,"activeCount":100},[],{"trials":3085,"activeCount":100},[],{"trials":3087,"activeCount":100},[],{"intervention":2558,"totalTrials":264,"cells":3089},{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3098,"PHASE3":3112,"PHASE4":3114,"NA":3116},{"trials":3091,"activeCount":100},[],{"trials":3093,"activeCount":100},[3094],{"nctId":1065,"briefTitle":1066,"status":229,"phases":3095,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":3096,"interventions":3097},[88],[584],[1074,1075,634,1076,1058],{"trials":3099,"activeCount":100},[3100,3104],{"nctId":2549,"briefTitle":2550,"status":229,"phases":3101,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":2555,"conditions":3102,"interventions":3103},[89],[1298],[2558,80,2559],{"nctId":3105,"briefTitle":3106,"status":973,"phases":3107,"primaryCompletion":3108,"completion":3109,"start":2962,"enrollment":100,"conditions":3110,"interventions":3111},"NCT01312493","Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab",[89],"2017-12","2018-12",[249],[2558],{"trials":3113,"activeCount":100},[],{"trials":3115,"activeCount":100},[],{"trials":3117,"activeCount":100},[],{"intervention":3119,"totalTrials":264,"cells":3120},"Metformin",{"EARLY_PHASE1":3121,"PHASE1":3140,"PHASE2":3142,"PHASE3":3154,"PHASE4":3156,"NA":3158},{"trials":3122,"activeCount":100},[3123,3133],{"nctId":3124,"briefTitle":3125,"status":229,"phases":3126,"primaryCompletion":3127,"completion":3127,"start":3128,"enrollment":126,"conditions":3129,"interventions":3132},"NCT01685762","Metformin for the Treatment of Endometrial Hyperplasia",[87],"2015-12-01","2013-01-10",[3130,3131],"Endometrial Hyperplasia","Endometrial Hyperplasia Without Atypia",[3119],{"nctId":3134,"briefTitle":3135,"status":229,"phases":3136,"primaryCompletion":2866,"completion":2866,"start":3137,"enrollment":19,"conditions":3138,"interventions":3139},"NCT01911247","Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer",[87],"2011-05",[34],[3119],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[3144],{"nctId":3145,"briefTitle":3146,"status":229,"phases":3147,"primaryCompletion":3148,"completion":3149,"start":3150,"enrollment":139,"conditions":3151,"interventions":3153},"NCT02035787","Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients",[89],"2023-10-12","2024-04-12","2014-02-27",[3152,34],"Complex Atypical Hyperplasia",[3119],{"trials":3155,"activeCount":100},[],{"trials":3157,"activeCount":100},[],{"trials":3159,"activeCount":100},[],{"intervention":1089,"totalTrials":264,"cells":3161},{"EARLY_PHASE1":3162,"PHASE1":3164,"PHASE2":3177,"PHASE3":3183,"PHASE4":3185,"NA":3187},{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[3166,3170],{"nctId":1078,"briefTitle":1079,"status":229,"phases":3167,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":549,"conditions":3168,"interventions":3169},[88],[1085,1086,1087],[969,1089,1058,1089,1090],{"nctId":3171,"briefTitle":3172,"status":229,"phases":3173,"primaryCompletion":581,"completion":1150,"start":2911,"enrollment":126,"conditions":3174,"interventions":3175},"NCT00307255","Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors",[88],[584],[1089,3176],"paclitaxel albumin-stabilized nanoparticle formulation",{"trials":3178,"activeCount":100},[3179],{"nctId":2917,"briefTitle":2918,"status":229,"phases":3180,"primaryCompletion":2920,"completion":2921,"start":2922,"enrollment":2923,"conditions":3181,"interventions":3182},[89],[24],[969,1089],{"trials":3184,"activeCount":100},[],{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"intervention":968,"totalTrials":264,"cells":3190},{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3195,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[3197,3201,3205],{"nctId":959,"briefTitle":960,"status":229,"phases":3198,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":3199,"interventions":3200},[88,89],[24],[968,371,969,351],{"nctId":1291,"briefTitle":1292,"status":229,"phases":3202,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":1296,"conditions":3203,"interventions":3204},[89],[1298],[1300,1131,1301,1302],{"nctId":1022,"briefTitle":1023,"status":229,"phases":3206,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":788,"conditions":3207,"interventions":3208},[89],[24],[968,371,969,588],{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"intervention":647,"totalTrials":264,"cells":3216},{"EARLY_PHASE1":3217,"PHASE1":3223,"PHASE2":3229,"PHASE3":3235,"PHASE4":3237,"NA":3239},{"trials":3218,"activeCount":100},[3219],{"nctId":2817,"briefTitle":2818,"status":229,"phases":3220,"primaryCompletion":2820,"completion":2820,"start":2821,"enrollment":445,"conditions":3221,"interventions":3222},[87],[2823],[2825,2826,2827],{"trials":3224,"activeCount":100},[3225],{"nctId":2831,"briefTitle":2832,"status":229,"phases":3226,"primaryCompletion":2834,"completion":2835,"start":2836,"enrollment":939,"conditions":3227,"interventions":3228},[88],[1749],[2839,2840,2841,2825,647],{"trials":3230,"activeCount":100},[3231],{"nctId":636,"briefTitle":637,"status":229,"phases":3232,"primaryCompletion":639,"completion":640,"start":641,"enrollment":336,"conditions":3233,"interventions":3234},[89],[249,643],[645,646,647,461,461],{"trials":3236,"activeCount":100},[],{"trials":3238,"activeCount":100},[],{"trials":3240,"activeCount":100},[],{"intervention":814,"totalTrials":264,"cells":3242},{"EARLY_PHASE1":3243,"PHASE1":3245,"PHASE2":3255,"PHASE3":3261,"PHASE4":3263,"NA":3265},{"trials":3244,"activeCount":100},[],{"trials":3246,"activeCount":100},[3247,3251],{"nctId":935,"briefTitle":936,"status":229,"phases":3248,"primaryCompletion":628,"completion":581,"start":938,"enrollment":939,"conditions":3249,"interventions":3250},[88],[584],[645,814,814,814],{"nctId":804,"briefTitle":805,"status":403,"phases":3252,"primaryCompletion":807,"completion":808,"start":809,"enrollment":9,"conditions":3253,"interventions":3254},[88],[811],[46,645,813,814,815],{"trials":3256,"activeCount":100},[3257],{"nctId":1031,"briefTitle":1032,"status":403,"phases":3258,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":3259,"interventions":3260},[89],[1039],[645,814],{"trials":3262,"activeCount":100},[],{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[],{"intervention":3268,"totalTrials":233,"cells":3269},"68Ga-HBED-CC-PSMA",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3292,"PHASE4":3294,"NA":3296},{"trials":3271,"activeCount":100},[],{"trials":3273,"activeCount":100},[],{"trials":3275,"activeCount":100},[3276,3284],{"nctId":3277,"briefTitle":3278,"status":973,"phases":3279,"primaryCompletion":3280,"completion":3280,"start":3281,"enrollment":100,"conditions":3282,"interventions":3283},"NCT04243941","PSMA-PET\u002FMRI Low- and Intermediate-Risk Prostate Cancer",[89],"2024-02-07","2022-11-29",[32],[3268],{"nctId":3285,"briefTitle":3286,"status":403,"phases":3287,"primaryCompletion":3280,"completion":3288,"start":3289,"enrollment":2714,"conditions":3290,"interventions":3291},"NCT04176497","PSMA-PET\u002FMRI Unfavorable-Risk Target Volume Pilot Study",[89],"2024-10-25","2020-07-16",[32],[3268],{"trials":3293,"activeCount":100},[],{"trials":3295,"activeCount":100},[],{"trials":3297,"activeCount":100},[],{"intervention":3299,"totalTrials":233,"cells":3300},"Pazopanib",{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3305,"PHASE3":3324,"PHASE4":3326,"NA":3328},{"trials":3302,"activeCount":100},[],{"trials":3304,"activeCount":100},[],{"trials":3306,"activeCount":100},[3307,3318],{"nctId":3308,"briefTitle":3309,"status":229,"phases":3310,"primaryCompletion":3311,"completion":3312,"start":3313,"enrollment":3314,"conditions":3315,"interventions":3317},"NCT01361113","Neoadjuvant Pazopanib in Renal Cell Carcinoma",[89],"2015-01-07","2017-02-15","2011-06",21,[3316],"Renal Cell Carcinoma",[3299],{"nctId":3319,"briefTitle":3320,"status":229,"phases":3321,"primaryCompletion":2920,"completion":2921,"start":1109,"enrollment":27,"conditions":3322,"interventions":3323},"NCT01262820","Pazopanib In Stage IIIB\u002FIV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab",[89],[24],[3299],{"trials":3325,"activeCount":100},[],{"trials":3327,"activeCount":100},[],{"trials":3329,"activeCount":100},[],{"intervention":957,"totalTrials":233,"cells":3331},{"EARLY_PHASE1":3332,"PHASE1":3334,"PHASE2":3336,"PHASE3":3351,"PHASE4":3353,"NA":3355},{"trials":3333,"activeCount":100},[],{"trials":3335,"activeCount":100},[],{"trials":3337,"activeCount":100},[3338,3342],{"nctId":949,"briefTitle":950,"status":229,"phases":3339,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":3340,"interventions":3341},[89],[24],[371,957],{"nctId":3343,"briefTitle":3344,"status":229,"phases":3345,"primaryCompletion":3346,"completion":3347,"start":309,"enrollment":549,"conditions":3348,"interventions":3349},"NCT00225420","Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer",[88,89],"2010-06","2012-08",[32],[957,3350],"leuprolide acetate",{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":100},[],{"trials":3356,"activeCount":100},[],{"intervention":1301,"totalTrials":233,"cells":3358},{"EARLY_PHASE1":3359,"PHASE1":3361,"PHASE2":3372,"PHASE3":3378,"PHASE4":3380,"NA":3382},{"trials":3360,"activeCount":100},[],{"trials":3362,"activeCount":100},[3363],{"nctId":3364,"briefTitle":3365,"status":229,"phases":3366,"primaryCompletion":3367,"completion":3367,"start":3368,"enrollment":549,"conditions":3369,"interventions":3371},"NCT01859858","Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors",[88],"2016-10-05","2013-06",[3370],"Advanced Colorectal Cancer",[1301],{"trials":3373,"activeCount":100},[3374],{"nctId":1291,"briefTitle":1292,"status":229,"phases":3375,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":1296,"conditions":3376,"interventions":3377},[89],[1298],[1300,1131,1301,1302],{"trials":3379,"activeCount":100},[],{"trials":3381,"activeCount":100},[],{"trials":3383,"activeCount":100},[],{"intervention":2871,"totalTrials":233,"cells":3385},{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3390,"PHASE3":3415,"PHASE4":3417,"NA":3419},{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[3392,3411],{"nctId":3393,"briefTitle":3394,"status":229,"phases":3395,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":3399,"conditions":3400,"interventions":3404},"NCT00448201","Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease",[89],"2011-01-11","2012-05-23","2011-01-07",71,[3401,3402,21,2965,3403],"Chronic Myeloproliferative Disorders","Leukemia","Myelodysplastic Syndromes",[3405,2871,3406,3407,3408,3409,3410],"anti-thymocyte globulin","therapeutic allogeneic lymphocytes","busulfan","fludarabine phosphate","methotrexate","tacrolimus",{"nctId":2863,"briefTitle":2864,"status":229,"phases":3412,"primaryCompletion":2866,"completion":2867,"start":2868,"enrollment":22,"conditions":3413,"interventions":3414},[89],[15],[2871,2860,349,2861],{"trials":3416,"activeCount":100},[],{"trials":3418,"activeCount":100},[],{"trials":3420,"activeCount":100},[],{"intervention":3406,"totalTrials":233,"cells":3422},{"EARLY_PHASE1":3423,"PHASE1":3425,"PHASE2":3427,"PHASE3":3443,"PHASE4":3445,"NA":3447},{"trials":3424,"activeCount":100},[],{"trials":3426,"activeCount":100},[],{"trials":3428,"activeCount":100},[3429,3433],{"nctId":3393,"briefTitle":3394,"status":229,"phases":3430,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":3399,"conditions":3431,"interventions":3432},[89],[3401,3402,21,2965,3403],[3405,2871,3406,3407,3408,3409,3410],{"nctId":3434,"briefTitle":3435,"status":229,"phases":3436,"primaryCompletion":3437,"completion":3437,"start":3438,"enrollment":3439,"conditions":3440,"interventions":3441},"NCT00448357","Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen",[88,89],"2015-11","2005-10",54,[3401,3402,21,2965,3403],[3442,3406,3407,3408,3410,3409],"rabbit anti-thymocyte globulin",{"trials":3444,"activeCount":100},[],{"trials":3446,"activeCount":100},[],{"trials":3448,"activeCount":100},[],{"intervention":3407,"totalTrials":233,"cells":3450},{"EARLY_PHASE1":3451,"PHASE1":3453,"PHASE2":3455,"PHASE3":3465,"PHASE4":3467,"NA":3469},{"trials":3452,"activeCount":100},[],{"trials":3454,"activeCount":100},[],{"trials":3456,"activeCount":100},[3457,3461],{"nctId":3393,"briefTitle":3394,"status":229,"phases":3458,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":3399,"conditions":3459,"interventions":3460},[89],[3401,3402,21,2965,3403],[3405,2871,3406,3407,3408,3409,3410],{"nctId":3434,"briefTitle":3435,"status":229,"phases":3462,"primaryCompletion":3437,"completion":3437,"start":3438,"enrollment":3439,"conditions":3463,"interventions":3464},[88,89],[3401,3402,21,2965,3403],[3442,3406,3407,3408,3410,3409],{"trials":3466,"activeCount":100},[],{"trials":3468,"activeCount":100},[],{"trials":3470,"activeCount":100},[],{"intervention":3408,"totalTrials":233,"cells":3472},{"EARLY_PHASE1":3473,"PHASE1":3475,"PHASE2":3477,"PHASE3":3487,"PHASE4":3489,"NA":3491},{"trials":3474,"activeCount":100},[],{"trials":3476,"activeCount":100},[],{"trials":3478,"activeCount":100},[3479,3483],{"nctId":3393,"briefTitle":3394,"status":229,"phases":3480,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":3399,"conditions":3481,"interventions":3482},[89],[3401,3402,21,2965,3403],[3405,2871,3406,3407,3408,3409,3410],{"nctId":3434,"briefTitle":3435,"status":229,"phases":3484,"primaryCompletion":3437,"completion":3437,"start":3438,"enrollment":3439,"conditions":3485,"interventions":3486},[88,89],[3401,3402,21,2965,3403],[3442,3406,3407,3408,3410,3409],{"trials":3488,"activeCount":100},[],{"trials":3490,"activeCount":100},[],{"trials":3492,"activeCount":100},[],{"intervention":3409,"totalTrials":233,"cells":3494},{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3499,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3496,"activeCount":100},[],{"trials":3498,"activeCount":100},[],{"trials":3500,"activeCount":100},[3501,3505],{"nctId":3393,"briefTitle":3394,"status":229,"phases":3502,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":3399,"conditions":3503,"interventions":3504},[89],[3401,3402,21,2965,3403],[3405,2871,3406,3407,3408,3409,3410],{"nctId":3434,"briefTitle":3435,"status":229,"phases":3506,"primaryCompletion":3437,"completion":3437,"start":3438,"enrollment":3439,"conditions":3507,"interventions":3508},[88,89],[3401,3402,21,2965,3403],[3442,3406,3407,3408,3410,3409],{"trials":3510,"activeCount":100},[],{"trials":3512,"activeCount":100},[],{"trials":3514,"activeCount":100},[],{"intervention":350,"totalTrials":233,"cells":3516},{"EARLY_PHASE1":3517,"PHASE1":3519,"PHASE2":3531,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3518,"activeCount":100},[],{"trials":3520,"activeCount":100},[3521],{"nctId":3522,"briefTitle":3523,"status":229,"phases":3524,"primaryCompletion":3525,"completion":3526,"start":3527,"enrollment":513,"conditions":3528,"interventions":3529},"NCT01011010","Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery",[88],"2012-12","2017-09-29","2009-07-22",[1112],[350,3530,589],"mitomycin C",{"trials":3532,"activeCount":100},[3533],{"nctId":340,"briefTitle":341,"status":229,"phases":3534,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":3535,"interventions":3536},[89],[15],[349,172,350,351],{"trials":3538,"activeCount":100},[],{"trials":3540,"activeCount":100},[],{"trials":3542,"activeCount":100},[],{"intervention":2801,"totalTrials":233,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3553,"PHASE3":3559,"PHASE4":3561,"NA":3563},{"trials":3546,"activeCount":100},[],{"trials":3548,"activeCount":100},[3549],{"nctId":2907,"briefTitle":2908,"status":229,"phases":3550,"primaryCompletion":1150,"completion":2910,"start":2911,"enrollment":2162,"conditions":3551,"interventions":3552},[88],[584],[969,588,2801],{"trials":3554,"activeCount":100},[3555],{"nctId":2794,"briefTitle":2795,"status":403,"phases":3556,"primaryCompletion":2797,"completion":975,"start":2798,"enrollment":126,"conditions":3557,"interventions":3558},[89],[24],[979,2801],{"trials":3560,"activeCount":100},[],{"trials":3562,"activeCount":100},[],{"trials":3564,"activeCount":100},[],{"intervention":3566,"totalTrials":233,"cells":3567},"mFOLFOX6",{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3584,"PHASE3":3598,"PHASE4":3600,"NA":3602},{"trials":3569,"activeCount":100},[],{"trials":3571,"activeCount":100},[3572],{"nctId":3573,"briefTitle":3574,"status":229,"phases":3575,"primaryCompletion":3576,"completion":3577,"start":3578,"enrollment":22,"conditions":3579,"interventions":3582},"NCT01571024","BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer",[88],"2015-05","2016-03","2012-05",[3580,3581,1331],"Advanced Solid Tumors","Metastatic Colorectal Cancer",[3583,3566],"BKM120",{"trials":3585,"activeCount":100},[3586],{"nctId":3587,"briefTitle":3588,"status":973,"phases":3589,"primaryCompletion":3590,"completion":3591,"start":3592,"enrollment":100,"conditions":3593,"interventions":3595},"NCT04418895","Neoadjuvant Therapy for Localized Rectal Adenocarcinoma",[89],"2022-05","2025-05","2021-08-13",[3594],"Rectal Adenocarcinoma",[3566,3596,3597],"CAPOX","fluoropyrimidine +\u002F- oxaliplatin",{"trials":3599,"activeCount":100},[],{"trials":3601,"activeCount":100},[],{"trials":3603,"activeCount":100},[],{"intervention":3605,"totalTrials":233,"cells":3606},"lapatinib ditosylate",{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3620,"PHASE3":3629,"PHASE4":3631,"NA":3633},{"trials":3608,"activeCount":100},[],{"trials":3610,"activeCount":100},[3611],{"nctId":3612,"briefTitle":3613,"status":229,"phases":3614,"primaryCompletion":3346,"completion":3347,"start":1036,"enrollment":139,"conditions":3615,"interventions":3616},"NCT00379509","Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer",[88],[15],[3605,3617,3618,3619],"TdT-mediated dUTP nick end labeling assay","gene expression analysis","microarray analysis",{"trials":3621,"activeCount":100},[3622],{"nctId":3623,"briefTitle":3624,"status":229,"phases":3625,"primaryCompletion":3626,"completion":1068,"start":3438,"enrollment":503,"conditions":3627,"interventions":3628},"NCT00246753","Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy",[89],"2012-07",[32],[3605],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":100},[],{"trials":3634,"activeCount":100},[],{"intervention":2860,"totalTrials":233,"cells":3636},{"EARLY_PHASE1":3637,"PHASE1":3639,"PHASE2":3641,"PHASE3":3651,"PHASE4":3653,"NA":3655},{"trials":3638,"activeCount":100},[],{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":100},[3643,3647],{"nctId":2853,"briefTitle":2854,"status":403,"phases":3644,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":2555,"conditions":3645,"interventions":3646},[89],[15],[2860,349,2861],{"nctId":2863,"briefTitle":2864,"status":229,"phases":3648,"primaryCompletion":2866,"completion":2867,"start":2868,"enrollment":22,"conditions":3649,"interventions":3650},[89],[15],[2871,2860,349,2861],{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[],{"intervention":2861,"totalTrials":233,"cells":3658},{"EARLY_PHASE1":3659,"PHASE1":3661,"PHASE2":3663,"PHASE3":3673,"PHASE4":3675,"NA":3677},{"trials":3660,"activeCount":100},[],{"trials":3662,"activeCount":100},[],{"trials":3664,"activeCount":100},[3665,3669],{"nctId":2853,"briefTitle":2854,"status":403,"phases":3666,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":2555,"conditions":3667,"interventions":3668},[89],[15],[2860,349,2861],{"nctId":2863,"briefTitle":2864,"status":229,"phases":3670,"primaryCompletion":2866,"completion":2867,"start":2868,"enrollment":22,"conditions":3671,"interventions":3672},[89],[15],[2871,2860,349,2861],{"trials":3674,"activeCount":100},[],{"trials":3676,"activeCount":100},[],{"trials":3678,"activeCount":100},[],{"intervention":2983,"totalTrials":233,"cells":3680},{"EARLY_PHASE1":3681,"PHASE1":3683,"PHASE2":3689,"PHASE3":3695,"PHASE4":3697,"NA":3699},{"trials":3682,"activeCount":100},[],{"trials":3684,"activeCount":100},[3685],{"nctId":2959,"briefTitle":2960,"status":403,"phases":3686,"primaryCompletion":2962,"completion":2963,"start":1150,"enrollment":1351,"conditions":3687,"interventions":3688},[88],[2965],[1156,2967,2968],{"trials":3690,"activeCount":100},[3691],{"nctId":2976,"briefTitle":2977,"status":973,"phases":3692,"primaryCompletion":2979,"completion":2980,"start":2161,"enrollment":100,"conditions":3693,"interventions":3694},[89],[722],[2983,738,2984],{"trials":3696,"activeCount":100},[],{"trials":3698,"activeCount":100},[],{"trials":3700,"activeCount":100},[],{"intervention":683,"totalTrials":233,"cells":3702},{"EARLY_PHASE1":3703,"PHASE1":3705,"PHASE2":3707,"PHASE3":3722,"PHASE4":3724,"NA":3726},{"trials":3704,"activeCount":100},[],{"trials":3706,"activeCount":100},[],{"trials":3708,"activeCount":100},[3709,3713],{"nctId":674,"briefTitle":675,"status":229,"phases":3710,"primaryCompletion":677,"completion":678,"start":679,"enrollment":30,"conditions":3711,"interventions":3712},[89],[632],[682,461,683],{"nctId":3714,"briefTitle":3715,"status":403,"phases":3716,"primaryCompletion":3717,"completion":964,"start":2955,"enrollment":3718,"conditions":3719,"interventions":3720},"NCT00073970","Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy",[89],"2005-06",37,[32],[3721],"celecoxib",{"trials":3723,"activeCount":100},[],{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[],{"intervention":3729,"totalTrials":233,"cells":3730},"Perflutren lipid microsphere",{"EARLY_PHASE1":3731,"PHASE1":3733,"PHASE2":3735,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3732,"activeCount":100},[],{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[3737,3747],{"nctId":3738,"briefTitle":3739,"status":229,"phases":3740,"primaryCompletion":3741,"completion":3741,"start":3742,"enrollment":478,"conditions":3743,"interventions":3745},"NCT04021238","Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging",[89],"2022-08-05","2020-10-07",[3744],"Kidney Cancer",[3729,3746],"Sulfur hexafluoride lipid microspheres",{"nctId":3748,"briefTitle":3749,"status":229,"phases":3750,"primaryCompletion":2592,"completion":2592,"start":3751,"enrollment":27,"conditions":3752,"interventions":3755},"NCT03907657","Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau",[89],"2019-09-23",[3753,3754],"Von-Hippel Lindau","Kidney Disease, Chronic",[3729,3746],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[],{"trials":3761,"activeCount":100},[],{"intervention":3746,"totalTrials":233,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3768,"PHASE3":3778,"PHASE4":3780,"NA":3782},{"trials":3765,"activeCount":100},[],{"trials":3767,"activeCount":100},[],{"trials":3769,"activeCount":100},[3770,3774],{"nctId":3738,"briefTitle":3739,"status":229,"phases":3771,"primaryCompletion":3741,"completion":3741,"start":3742,"enrollment":478,"conditions":3772,"interventions":3773},[89],[3744],[3729,3746],{"nctId":3748,"briefTitle":3749,"status":229,"phases":3775,"primaryCompletion":2592,"completion":2592,"start":3751,"enrollment":27,"conditions":3776,"interventions":3777},[89],[3753,3754],[3729,3746],{"trials":3779,"activeCount":100},[],{"trials":3781,"activeCount":100},[],{"trials":3783,"activeCount":100},[],{"intervention":3077,"totalTrials":9,"cells":3785},{"EARLY_PHASE1":3786,"PHASE1":3788,"PHASE2":3790,"PHASE3":3796,"PHASE4":3798,"NA":3800},{"trials":3787,"activeCount":100},[],{"trials":3789,"activeCount":100},[],{"trials":3791,"activeCount":100},[3792],{"nctId":3070,"briefTitle":3071,"status":229,"phases":3793,"primaryCompletion":3073,"completion":3073,"start":2962,"enrollment":1016,"conditions":3794,"interventions":3795},[89],[3075],[2880,3077],{"trials":3797,"activeCount":100},[],{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[],{"intervention":3803,"totalTrials":9,"cells":3804},"18F-fluorofuranylnorprogesterone PET \u002F MRI",{"EARLY_PHASE1":3805,"PHASE1":3807,"PHASE2":3809,"PHASE3":3820,"PHASE4":3822,"NA":3824},{"trials":3806,"activeCount":100},[],{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[3811],{"nctId":3812,"briefTitle":3813,"status":973,"phases":3814,"primaryCompletion":3815,"completion":3816,"start":3817,"enrollment":100,"conditions":3818,"interventions":3819},"NCT05483023","18-fluorofuranylnorprogesterone (FFNP) PET\u002FMRI as a Potential Biomarker of Response to Progesterone Therapy",[89],"2026-06-28","2027-12","2024-02-15",[3152,34],[3803],{"trials":3821,"activeCount":100},[],{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[],{"intervention":2559,"totalTrials":9,"cells":3827},{"EARLY_PHASE1":3828,"PHASE1":3830,"PHASE2":3832,"PHASE3":3838,"PHASE4":3840,"NA":3842},{"trials":3829,"activeCount":100},[],{"trials":3831,"activeCount":100},[],{"trials":3833,"activeCount":100},[3834],{"nctId":2549,"briefTitle":2550,"status":229,"phases":3835,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":2555,"conditions":3836,"interventions":3837},[89],[1298],[2558,80,2559],{"trials":3839,"activeCount":100},[],{"trials":3841,"activeCount":100},[],{"trials":3843,"activeCount":100},[],{"intervention":980,"totalTrials":9,"cells":3845},{"EARLY_PHASE1":3846,"PHASE1":3848,"PHASE2":3850,"PHASE3":3856,"PHASE4":3858,"NA":3860},{"trials":3847,"activeCount":100},[],{"trials":3849,"activeCount":100},[],{"trials":3851,"activeCount":100},[3852],{"nctId":971,"briefTitle":972,"status":973,"phases":3853,"primaryCompletion":975,"completion":975,"start":976,"enrollment":100,"conditions":3854,"interventions":3855},[89],[24],[979,371,980],{"trials":3857,"activeCount":100},[],{"trials":3859,"activeCount":100},[],{"trials":3861,"activeCount":100},[],{"intervention":3863,"totalTrials":9,"cells":3864},"Artesunate vaginal inserts",{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3869,"PHASE3":3883,"PHASE4":3885,"NA":3887},{"trials":3866,"activeCount":100},[],{"trials":3868,"activeCount":100},[],{"trials":3870,"activeCount":100},[3871],{"nctId":3872,"briefTitle":3873,"status":229,"phases":3874,"primaryCompletion":3875,"completion":3875,"start":3876,"enrollment":3877,"conditions":3878,"interventions":3882},"NCT06519994","Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya",[89],"2026-04-08","2025-01-22",120,[3879,3880,3881],"Human Immunodeficiency Virus","Human Papillomavirus","Cervical Precancer",[3863],{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[],{"trials":3888,"activeCount":100},[],{"intervention":3890,"totalTrials":9,"cells":3891},"BRAF inhibitor dabrafenib and MEK inhibitor trametinib",{"EARLY_PHASE1":3892,"PHASE1":3894,"PHASE2":3896,"PHASE3":3911,"PHASE4":3913,"NA":3915},{"trials":3893,"activeCount":100},[],{"trials":3895,"activeCount":100},[],{"trials":3897,"activeCount":100},[3898],{"nctId":3899,"briefTitle":3900,"status":229,"phases":3901,"primaryCompletion":3902,"completion":3903,"start":3904,"enrollment":22,"conditions":3905,"interventions":3910},"NCT01726738","LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations",[89],"2017-11-03","2020-09-17","2013-04-04",[3906,3907,3908,3909],"Stage III Melanoma","Stage IV Melanoma","Unresectable Melanoma","BRAF Mutant Melanoma",[3890],{"trials":3912,"activeCount":100},[],{"trials":3914,"activeCount":100},[],{"trials":3916,"activeCount":100},[],{"intervention":3918,"totalTrials":9,"cells":3919},"Arsenic trioxide",{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3933,"PHASE4":3935,"NA":3937},{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"trials":3925,"activeCount":100},[3926],{"nctId":3927,"briefTitle":3928,"status":403,"phases":3929,"primaryCompletion":343,"completion":343,"start":1027,"enrollment":264,"conditions":3930,"interventions":3932},"NCT01184053","Trisenox® in Women With Metastatic Endometrial Cancer",[89],[3931],"Endometrial Carcinoma",[3918],{"trials":3934,"activeCount":100},[],{"trials":3936,"activeCount":100},[],{"trials":3938,"activeCount":100},[],{"intervention":3405,"totalTrials":9,"cells":3940},{"EARLY_PHASE1":3941,"PHASE1":3943,"PHASE2":3945,"PHASE3":3951,"PHASE4":3953,"NA":3955},{"trials":3942,"activeCount":100},[],{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":100},[3947],{"nctId":3393,"briefTitle":3394,"status":229,"phases":3948,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":3399,"conditions":3949,"interventions":3950},[89],[3401,3402,21,2965,3403],[3405,2871,3406,3407,3408,3409,3410],{"trials":3952,"activeCount":100},[],{"trials":3954,"activeCount":100},[],{"trials":3956,"activeCount":100},[],{"intervention":737,"totalTrials":9,"cells":3958},{"EARLY_PHASE1":3959,"PHASE1":3961,"PHASE2":3963,"PHASE3":3969,"PHASE4":3971,"NA":3973},{"trials":3960,"activeCount":100},[],{"trials":3962,"activeCount":100},[],{"trials":3964,"activeCount":100},[3965],{"nctId":727,"briefTitle":728,"status":415,"phases":3966,"primaryCompletion":730,"completion":731,"start":732,"enrollment":692,"conditions":3967,"interventions":3968},[89],[734,722,735],[737,725,738,662],{"trials":3970,"activeCount":100},[],{"trials":3972,"activeCount":100},[],{"trials":3974,"activeCount":100},[],{"intervention":3350,"totalTrials":9,"cells":3976},{"EARLY_PHASE1":3977,"PHASE1":3979,"PHASE2":3981,"PHASE3":3987,"PHASE4":3989,"NA":3991},{"trials":3978,"activeCount":100},[],{"trials":3980,"activeCount":100},[],{"trials":3982,"activeCount":100},[3983],{"nctId":3343,"briefTitle":3344,"status":229,"phases":3984,"primaryCompletion":3346,"completion":3347,"start":309,"enrollment":549,"conditions":3985,"interventions":3986},[88,89],[32],[957,3350],{"trials":3988,"activeCount":100},[],{"trials":3990,"activeCount":100},[],{"trials":3992,"activeCount":100},[],{"intervention":3994,"totalTrials":9,"cells":3995},"tamoxifen citrate",{"EARLY_PHASE1":3996,"PHASE1":3998,"PHASE2":4000,"PHASE3":4013,"PHASE4":4015,"NA":4017},{"trials":3997,"activeCount":100},[],{"trials":3999,"activeCount":100},[],{"trials":4001,"activeCount":100},[4002],{"nctId":4003,"briefTitle":4004,"status":229,"phases":4005,"primaryCompletion":4006,"completion":4007,"start":4008,"enrollment":4009,"conditions":4010,"interventions":4012},"NCT00764322","Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen",[89],"2010-09-28","2011-07-01","2008-06-18",501,[15,4011],"Menopausal Symptoms",[3994,3618],{"trials":4014,"activeCount":100},[],{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[],{"intervention":3442,"totalTrials":9,"cells":4020},{"EARLY_PHASE1":4021,"PHASE1":4023,"PHASE2":4025,"PHASE3":4031,"PHASE4":4033,"NA":4035},{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[],{"trials":4026,"activeCount":100},[4027],{"nctId":3434,"briefTitle":3435,"status":229,"phases":4028,"primaryCompletion":3437,"completion":3437,"start":3438,"enrollment":3439,"conditions":4029,"interventions":4030},[88,89],[3401,3402,21,2965,3403],[3442,3406,3407,3408,3410,3409],{"trials":4032,"activeCount":100},[],{"trials":4034,"activeCount":100},[],{"trials":4036,"activeCount":100},[],{"intervention":4038,"totalTrials":9,"cells":4039},"Herceptin",{"EARLY_PHASE1":4040,"PHASE1":4042,"PHASE2":4044,"PHASE3":4053,"PHASE4":4055,"NA":4057},{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[4046],{"nctId":4047,"briefTitle":4048,"status":229,"phases":4049,"primaryCompletion":964,"completion":976,"start":4050,"enrollment":205,"conditions":4051,"interventions":4052},"NCT00943410","Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer",[89],"2000-03",[15],[4038],{"trials":4054,"activeCount":100},[],{"trials":4056,"activeCount":100},[],{"trials":4058,"activeCount":100},[],{"intervention":4060,"totalTrials":9,"cells":4061},"Thiamine",{"EARLY_PHASE1":4062,"PHASE1":4064,"PHASE2":4066,"PHASE3":4080,"PHASE4":4082,"NA":4084},{"trials":4063,"activeCount":100},[],{"trials":4065,"activeCount":100},[],{"trials":4067,"activeCount":100},[4068],{"nctId":4069,"briefTitle":4070,"status":229,"phases":4071,"primaryCompletion":4072,"completion":4073,"start":2876,"enrollment":16,"conditions":4074,"interventions":4078},"NCT03263442","High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation",[89],"2020-03-02","2020-08-10",[4075,4076,4077],"Hematopoietic Stem Cell Transplantation","Delirium","Thiamine Deficiency",[4060,4079],"Normal saline",{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"trials":4085,"activeCount":100},[],{"intervention":4079,"totalTrials":9,"cells":4087},{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4092,"PHASE3":4098,"PHASE4":4100,"NA":4102},{"trials":4089,"activeCount":100},[],{"trials":4091,"activeCount":100},[],{"trials":4093,"activeCount":100},[4094],{"nctId":4069,"briefTitle":4070,"status":229,"phases":4095,"primaryCompletion":4072,"completion":4073,"start":2876,"enrollment":16,"conditions":4096,"interventions":4097},[89],[4075,4076,4077],[4060,4079],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[],{"intervention":659,"totalTrials":9,"cells":4105},{"EARLY_PHASE1":4106,"PHASE1":4108,"PHASE2":4110,"PHASE3":4116,"PHASE4":4118,"NA":4120},{"trials":4107,"activeCount":100},[],{"trials":4109,"activeCount":100},[],{"trials":4111,"activeCount":100},[4112],{"nctId":649,"briefTitle":650,"status":403,"phases":4113,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":4114,"interventions":4115},[89],[657],[659,65,660,661,461,662,663],{"trials":4117,"activeCount":100},[],{"trials":4119,"activeCount":100},[],{"trials":4121,"activeCount":100},[],{"intervention":660,"totalTrials":9,"cells":4123},{"EARLY_PHASE1":4124,"PHASE1":4126,"PHASE2":4128,"PHASE3":4134,"PHASE4":4136,"NA":4138},{"trials":4125,"activeCount":100},[],{"trials":4127,"activeCount":100},[],{"trials":4129,"activeCount":100},[4130],{"nctId":649,"briefTitle":650,"status":403,"phases":4131,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":4132,"interventions":4133},[89],[657],[659,65,660,661,461,662,663],{"trials":4135,"activeCount":100},[],{"trials":4137,"activeCount":100},[],{"trials":4139,"activeCount":100},[],{"intervention":663,"totalTrials":9,"cells":4141},{"EARLY_PHASE1":4142,"PHASE1":4144,"PHASE2":4146,"PHASE3":4152,"PHASE4":4154,"NA":4156},{"trials":4143,"activeCount":100},[],{"trials":4145,"activeCount":100},[],{"trials":4147,"activeCount":100},[4148],{"nctId":649,"briefTitle":650,"status":403,"phases":4149,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":4150,"interventions":4151},[89],[657],[659,65,660,661,461,662,663],{"trials":4153,"activeCount":100},[],{"trials":4155,"activeCount":100},[],{"trials":4157,"activeCount":100},[],{"intervention":4159,"totalTrials":9,"cells":4160},"pembrolizumab, gemcitabine and cisplatin",{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4165,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4162,"activeCount":100},[],{"trials":4164,"activeCount":100},[],{"trials":4166,"activeCount":100},[4167],{"nctId":4168,"briefTitle":4169,"status":229,"phases":4170,"primaryCompletion":4171,"completion":4172,"start":4173,"enrollment":692,"conditions":4174,"interventions":4175},"NCT02690558","Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy",[89],"2020-07-06","2026-01-30","2016-05",[29],[4159],{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[],{"intervention":239,"totalTrials":9,"cells":4183},{"EARLY_PHASE1":4184,"PHASE1":4186,"PHASE2":4188,"PHASE3":4194,"PHASE4":4196,"NA":4198},{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[4190],{"nctId":227,"briefTitle":228,"status":229,"phases":4191,"primaryCompletion":178,"completion":231,"start":232,"enrollment":233,"conditions":4192,"interventions":4193},[89],[235,236],[238,239,95],{"trials":4195,"activeCount":100},[],{"trials":4197,"activeCount":100},[],{"trials":4199,"activeCount":100},[],{"intervention":4201,"totalTrials":9,"cells":4202},"Pregabalin",{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4207,"PHASE3":4219,"PHASE4":4221,"NA":4223},{"trials":4204,"activeCount":100},[],{"trials":4206,"activeCount":100},[],{"trials":4208,"activeCount":100},[4209],{"nctId":4210,"briefTitle":4211,"status":403,"phases":4212,"primaryCompletion":4213,"completion":4214,"start":4215,"enrollment":513,"conditions":4216,"interventions":4218},"NCT03407430","Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain",[89],"2017-06-03","2017-07-20","2016-01-27",[15,21,4217],"Pain",[4201],{"trials":4220,"activeCount":100},[],{"trials":4222,"activeCount":100},[],{"trials":4224,"activeCount":100},[],{"intervention":2984,"totalTrials":9,"cells":4226},{"EARLY_PHASE1":4227,"PHASE1":4229,"PHASE2":4231,"PHASE3":4237,"PHASE4":4239,"NA":4241},{"trials":4228,"activeCount":100},[],{"trials":4230,"activeCount":100},[],{"trials":4232,"activeCount":100},[4233],{"nctId":2976,"briefTitle":2977,"status":973,"phases":4234,"primaryCompletion":2979,"completion":2980,"start":2161,"enrollment":100,"conditions":4235,"interventions":4236},[89],[722],[2983,738,2984],{"trials":4238,"activeCount":100},[],{"trials":4240,"activeCount":100},[],{"trials":4242,"activeCount":100},[],{"intervention":682,"totalTrials":9,"cells":4244},{"EARLY_PHASE1":4245,"PHASE1":4247,"PHASE2":4249,"PHASE3":4255,"PHASE4":4257,"NA":4259},{"trials":4246,"activeCount":100},[],{"trials":4248,"activeCount":100},[],{"trials":4250,"activeCount":100},[4251],{"nctId":674,"briefTitle":675,"status":229,"phases":4252,"primaryCompletion":677,"completion":678,"start":679,"enrollment":30,"conditions":4253,"interventions":4254},[89],[632],[682,461,683],{"trials":4256,"activeCount":100},[],{"trials":4258,"activeCount":100},[],{"trials":4260,"activeCount":100},[],{"intervention":370,"totalTrials":9,"cells":4262},{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4267,"PHASE3":4273,"PHASE4":4275,"NA":4277},{"trials":4264,"activeCount":100},[],{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[4269],{"nctId":361,"briefTitle":362,"status":229,"phases":4270,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":4271,"interventions":4272},[89],[15],[370,371,172,372,351],{"trials":4274,"activeCount":100},[],{"trials":4276,"activeCount":100},[],{"trials":4278,"activeCount":100},[],{"intervention":372,"totalTrials":9,"cells":4280},{"EARLY_PHASE1":4281,"PHASE1":4283,"PHASE2":4285,"PHASE3":4291,"PHASE4":4293,"NA":4295},{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[],{"trials":4286,"activeCount":100},[4287],{"nctId":361,"briefTitle":362,"status":229,"phases":4288,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":4289,"interventions":4290},[89],[15],[370,371,172,372,351],{"trials":4292,"activeCount":100},[],{"trials":4294,"activeCount":100},[],{"trials":4296,"activeCount":100},[],{"intervention":4298,"totalTrials":9,"cells":4299},"R-CHOP",{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4304,"PHASE3":4314,"PHASE4":4316,"NA":4318},{"trials":4301,"activeCount":100},[],{"trials":4303,"activeCount":100},[],{"trials":4305,"activeCount":100},[4306],{"nctId":4307,"briefTitle":4308,"status":229,"phases":4309,"primaryCompletion":4310,"completion":4311,"start":3577,"enrollment":692,"conditions":4312,"interventions":4313},"NCT02660710","Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma",[89],"2021-07-22","2022-07-22",[657,2655],[4298],{"trials":4315,"activeCount":100},[],{"trials":4317,"activeCount":100},[],{"trials":4319,"activeCount":100},[],{"intervention":4321,"totalTrials":9,"cells":4322},"Commercial CAR-T",{"EARLY_PHASE1":4323,"PHASE1":4325,"PHASE2":4327,"PHASE3":4341,"PHASE4":4343,"NA":4345},{"trials":4324,"activeCount":100},[],{"trials":4326,"activeCount":100},[],{"trials":4328,"activeCount":100},[4329],{"nctId":4330,"briefTitle":4331,"status":973,"phases":4332,"primaryCompletion":4333,"completion":4333,"start":4334,"enrollment":100,"conditions":4335,"interventions":4339},"NCT07071909","Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells",[88,89],"2025-08-29","2025-01-20",[4336,18,4337,21,3402,722,4338],"Malignancy","Hematological Malignancies","Solid Tumor",[4321,4340],"Investigational CAR-T",{"trials":4342,"activeCount":100},[],{"trials":4344,"activeCount":100},[],{"trials":4346,"activeCount":100},[],{"intervention":4340,"totalTrials":9,"cells":4348},{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4359,"PHASE4":4361,"NA":4363},{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[],{"trials":4354,"activeCount":100},[4355],{"nctId":4330,"briefTitle":4331,"status":973,"phases":4356,"primaryCompletion":4333,"completion":4333,"start":4334,"enrollment":100,"conditions":4357,"interventions":4358},[88,89],[4336,18,4337,21,3402,722,4338],[4321,4340],{"trials":4360,"activeCount":100},[],{"trials":4362,"activeCount":100},[],{"trials":4364,"activeCount":100},[],{"intervention":2571,"totalTrials":9,"cells":4366},{"EARLY_PHASE1":4367,"PHASE1":4369,"PHASE2":4371,"PHASE3":4377,"PHASE4":4379,"NA":4381},{"trials":4368,"activeCount":100},[],{"trials":4370,"activeCount":100},[],{"trials":4372,"activeCount":100},[4373],{"nctId":2561,"briefTitle":2562,"status":403,"phases":4374,"primaryCompletion":2564,"completion":2565,"start":2566,"enrollment":9,"conditions":4375,"interventions":4376},[88,89],[2568,2569,24],[2571,80],{"trials":4378,"activeCount":100},[],{"trials":4380,"activeCount":100},[],{"trials":4382,"activeCount":100},[],{"intervention":4384,"totalTrials":9,"cells":4385},"Ofatumumab",{"EARLY_PHASE1":4386,"PHASE1":4388,"PHASE2":4390,"PHASE3":4403,"PHASE4":4405,"NA":4407},{"trials":4387,"activeCount":100},[],{"trials":4389,"activeCount":100},[],{"trials":4391,"activeCount":100},[4392],{"nctId":4393,"briefTitle":4394,"status":973,"phases":4395,"primaryCompletion":1069,"completion":4396,"start":3313,"enrollment":100,"conditions":4397,"interventions":4402},"NCT01263418","Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas",[89],"2018-01",[774,4398,4399,4400,4401],"Lymphoma, Follicular","Lymphoma, B-Cell, Marginal Zone","Lymphoma, Low-Grade","Lymphoma, Intermediate-Grade",[4384],{"trials":4404,"activeCount":100},[],{"trials":4406,"activeCount":100},[],{"trials":4408,"activeCount":100},[],{"intervention":486,"totalTrials":9,"cells":4410},{"EARLY_PHASE1":4411,"PHASE1":4413,"PHASE2":4415,"PHASE3":4421,"PHASE4":4423,"NA":4425},{"trials":4412,"activeCount":100},[],{"trials":4414,"activeCount":100},[],{"trials":4416,"activeCount":100},[4417],{"nctId":472,"briefTitle":473,"status":229,"phases":4418,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":4419,"interventions":4420},[89],[480,481,482,483,484],[486,56,80],{"trials":4422,"activeCount":100},[],{"trials":4424,"activeCount":100},[],{"trials":4426,"activeCount":100},[],{"intervention":1019,"totalTrials":9,"cells":4428},{"EARLY_PHASE1":4429,"PHASE1":4431,"PHASE2":4433,"PHASE3":4439,"PHASE4":4441,"NA":4443},{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[4435],{"nctId":1012,"briefTitle":1013,"status":229,"phases":4436,"primaryCompletion":964,"completion":308,"start":1015,"enrollment":1016,"conditions":4437,"interventions":4438},[89],[469],[646,645,1019,1020],{"trials":4440,"activeCount":100},[],{"trials":4442,"activeCount":100},[],{"trials":4444,"activeCount":100},[],{"intervention":1020,"totalTrials":9,"cells":4446},{"EARLY_PHASE1":4447,"PHASE1":4449,"PHASE2":4451,"PHASE3":4457,"PHASE4":4459,"NA":4461},{"trials":4448,"activeCount":100},[],{"trials":4450,"activeCount":100},[],{"trials":4452,"activeCount":100},[4453],{"nctId":1012,"briefTitle":1013,"status":229,"phases":4454,"primaryCompletion":964,"completion":308,"start":1015,"enrollment":1016,"conditions":4455,"interventions":4456},[89],[469],[646,645,1019,1020],{"trials":4458,"activeCount":100},[],{"trials":4460,"activeCount":100},[],{"trials":4462,"activeCount":100},[],{"intervention":4464,"totalTrials":9,"cells":4465},"Regorafenib",{"EARLY_PHASE1":4466,"PHASE1":4468,"PHASE2":4470,"PHASE3":4484,"PHASE4":4486,"NA":4488},{"trials":4467,"activeCount":100},[],{"trials":4469,"activeCount":100},[],{"trials":4471,"activeCount":100},[4472],{"nctId":4473,"briefTitle":4474,"status":229,"phases":4475,"primaryCompletion":4476,"completion":4477,"start":4478,"enrollment":4479,"conditions":4480,"interventions":4482},"NCT01298570","Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer",[89],"2016-11-15","2020-10-02","2011-04-07",181,[4481],"Colorectal Cancer Metastatic",[4464,4483,4483],"FOLFIRI",{"trials":4485,"activeCount":100},[],{"trials":4487,"activeCount":100},[],{"trials":4489,"activeCount":100},[],{"intervention":4483,"totalTrials":9,"cells":4491},{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4502,"PHASE4":4504,"NA":4506},{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[],{"trials":4497,"activeCount":100},[4498],{"nctId":4473,"briefTitle":4474,"status":229,"phases":4499,"primaryCompletion":4476,"completion":4477,"start":4478,"enrollment":4479,"conditions":4500,"interventions":4501},[89],[4481],[4464,4483,4483],{"trials":4503,"activeCount":100},[],{"trials":4505,"activeCount":100},[],{"trials":4507,"activeCount":100},[],{"intervention":2881,"totalTrials":9,"cells":4509},{"EARLY_PHASE1":4510,"PHASE1":4512,"PHASE2":4514,"PHASE3":4520,"PHASE4":4522,"NA":4524},{"trials":4511,"activeCount":100},[],{"trials":4513,"activeCount":100},[],{"trials":4515,"activeCount":100},[4516],{"nctId":2873,"briefTitle":2874,"status":229,"phases":4517,"primaryCompletion":547,"completion":2876,"start":1082,"enrollment":1351,"conditions":4518,"interventions":4519},[89],[2878],[2880,2881,2825],{"trials":4521,"activeCount":100},[],{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"intervention":4527,"totalTrials":9,"cells":4528},"octreotide acetate",{"EARLY_PHASE1":4529,"PHASE1":4531,"PHASE2":4533,"PHASE3":4544,"PHASE4":4546,"NA":4548},{"trials":4530,"activeCount":100},[],{"trials":4532,"activeCount":100},[],{"trials":4534,"activeCount":100},[4535],{"nctId":4536,"briefTitle":4537,"status":229,"phases":4538,"primaryCompletion":4539,"completion":4540,"start":4541,"enrollment":582,"conditions":4542,"interventions":4543},"NCT00257426","Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer",[89],"2007-02","2009-09","2005-07",[1112],[4527],{"trials":4545,"activeCount":100},[],{"trials":4547,"activeCount":100},[],{"trials":4549,"activeCount":100},[],{"intervention":4551,"totalTrials":9,"cells":4552},"Neoadjuvant Cisplatin, nab-paclitaxel",{"EARLY_PHASE1":4553,"PHASE1":4555,"PHASE2":4557,"PHASE3":4569,"PHASE4":4571,"NA":4573},{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":100},[],{"trials":4558,"activeCount":100},[4559],{"nctId":4560,"briefTitle":4561,"status":403,"phases":4562,"primaryCompletion":4563,"completion":4563,"start":2979,"enrollment":9,"conditions":4564,"interventions":4566},"NCT02276560","Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC",[89],"2016-06",[4565],"Stage IIIA Non-Small Cell Lung Cancer",[4551,4567,4568],"Adjuvant Cisplatin,nab-paclitaxel","Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine",{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":100},[],{"trials":4574,"activeCount":100},[],{"intervention":4567,"totalTrials":9,"cells":4576},{"EARLY_PHASE1":4577,"PHASE1":4579,"PHASE2":4581,"PHASE3":4587,"PHASE4":4589,"NA":4591},{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[4583],{"nctId":4560,"briefTitle":4561,"status":403,"phases":4584,"primaryCompletion":4563,"completion":4563,"start":2979,"enrollment":9,"conditions":4585,"interventions":4586},[89],[4565],[4551,4567,4568],{"trials":4588,"activeCount":100},[],{"trials":4590,"activeCount":100},[],{"trials":4592,"activeCount":100},[],{"intervention":4568,"totalTrials":9,"cells":4594},{"EARLY_PHASE1":4595,"PHASE1":4597,"PHASE2":4599,"PHASE3":4605,"PHASE4":4607,"NA":4609},{"trials":4596,"activeCount":100},[],{"trials":4598,"activeCount":100},[],{"trials":4600,"activeCount":100},[4601],{"nctId":4560,"briefTitle":4561,"status":403,"phases":4602,"primaryCompletion":4563,"completion":4563,"start":2979,"enrollment":9,"conditions":4603,"interventions":4604},[89],[4565],[4551,4567,4568],{"trials":4606,"activeCount":100},[],{"trials":4608,"activeCount":100},[],{"trials":4610,"activeCount":100},[],{"intervention":4612,"totalTrials":9,"cells":4613},"CRLX101",{"EARLY_PHASE1":4614,"PHASE1":4616,"PHASE2":4618,"PHASE3":4629,"PHASE4":4631,"NA":4633},{"trials":4615,"activeCount":100},[],{"trials":4617,"activeCount":100},[],{"trials":4619,"activeCount":100},[4620],{"nctId":4621,"briefTitle":4622,"status":403,"phases":4623,"primaryCompletion":4624,"completion":4625,"start":546,"enrollment":1351,"conditions":4626,"interventions":4628},"NCT02010567","Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer",[88,89],"2016-09-16","2019-06-25",[4627],"Rectal Cancer",[4612,2840],{"trials":4630,"activeCount":100},[],{"trials":4632,"activeCount":100},[],{"trials":4634,"activeCount":100},[],{"intervention":4636,"totalTrials":9,"cells":4637},"pembrolizumab,",{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4642,"PHASE3":4653,"PHASE4":4655,"NA":4657},{"trials":4639,"activeCount":100},[],{"trials":4641,"activeCount":100},[],{"trials":4643,"activeCount":100},[4644],{"nctId":4645,"briefTitle":4646,"status":229,"phases":4647,"primaryCompletion":4648,"completion":4649,"start":1436,"enrollment":788,"conditions":4650,"interventions":4652},"NCT02768792","High Dose Cytarabine Followed by Pembrolizumab in Relapsed\u002FRefractory AML",[89],"2019-11-27","2024-06-20",[4651],"Acute Myeloid Leukemia, in Relapse",[4636],{"trials":4654,"activeCount":100},[],{"trials":4656,"activeCount":100},[],{"trials":4658,"activeCount":100},[],{"intervention":4660,"totalTrials":9,"cells":4661},"PS-341",{"EARLY_PHASE1":4662,"PHASE1":4664,"PHASE2":4666,"PHASE3":4679,"PHASE4":4681,"NA":4683},{"trials":4663,"activeCount":100},[],{"trials":4665,"activeCount":100},[],{"trials":4667,"activeCount":100},[4668],{"nctId":4669,"briefTitle":4670,"status":229,"phases":4671,"primaryCompletion":4672,"completion":2910,"start":4673,"enrollment":4674,"conditions":4675,"interventions":4676},"NCT00237627","Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer",[88,89],"2006-12","2001-05",107,[15,3402,21,2965,113,584],[4660,4677,4678],"Doxil","Velcade",{"trials":4680,"activeCount":100},[],{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":100},[],{"intervention":4677,"totalTrials":9,"cells":4686},{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4691,"PHASE3":4697,"PHASE4":4699,"NA":4701},{"trials":4688,"activeCount":100},[],{"trials":4690,"activeCount":100},[],{"trials":4692,"activeCount":100},[4693],{"nctId":4669,"briefTitle":4670,"status":229,"phases":4694,"primaryCompletion":4672,"completion":2910,"start":4673,"enrollment":4674,"conditions":4695,"interventions":4696},[88,89],[15,3402,21,2965,113,584],[4660,4677,4678],{"trials":4698,"activeCount":100},[],{"trials":4700,"activeCount":100},[],{"trials":4702,"activeCount":100},[],{"intervention":4678,"totalTrials":9,"cells":4704},{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4709,"PHASE3":4715,"PHASE4":4717,"NA":4719},{"trials":4706,"activeCount":100},[],{"trials":4708,"activeCount":100},[],{"trials":4710,"activeCount":100},[4711],{"nctId":4669,"briefTitle":4670,"status":229,"phases":4712,"primaryCompletion":4672,"completion":2910,"start":4673,"enrollment":4674,"conditions":4713,"interventions":4714},[88,89],[15,3402,21,2965,113,584],[4660,4677,4678],{"trials":4716,"activeCount":100},[],{"trials":4718,"activeCount":100},[],{"trials":4720,"activeCount":100},[],{"intervention":3596,"totalTrials":9,"cells":4722},{"EARLY_PHASE1":4723,"PHASE1":4725,"PHASE2":4727,"PHASE3":4733,"PHASE4":4735,"NA":4737},{"trials":4724,"activeCount":100},[],{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[4729],{"nctId":3587,"briefTitle":3588,"status":973,"phases":4730,"primaryCompletion":3590,"completion":3591,"start":3592,"enrollment":100,"conditions":4731,"interventions":4732},[89],[3594],[3566,3596,3597],{"trials":4734,"activeCount":100},[],{"trials":4736,"activeCount":100},[],{"trials":4738,"activeCount":100},[],{"intervention":3597,"totalTrials":9,"cells":4740},{"EARLY_PHASE1":4741,"PHASE1":4743,"PHASE2":4745,"PHASE3":4751,"PHASE4":4753,"NA":4755},{"trials":4742,"activeCount":100},[],{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[4747],{"nctId":3587,"briefTitle":3588,"status":973,"phases":4748,"primaryCompletion":3590,"completion":3591,"start":3592,"enrollment":100,"conditions":4749,"interventions":4750},[89],[3594],[3566,3596,3597],{"trials":4752,"activeCount":100},[],{"trials":4754,"activeCount":100},[],{"trials":4756,"activeCount":100},[],{"intervention":589,"totalTrials":155,"cells":4758},{"EARLY_PHASE1":4759,"PHASE1":4768,"PHASE2":4785,"PHASE3":4787,"PHASE4":4789,"NA":4791},{"trials":4760,"activeCount":100},[4761],{"nctId":4762,"briefTitle":4763,"status":229,"phases":4764,"primaryCompletion":579,"completion":4765,"start":677,"enrollment":1037,"conditions":4766,"interventions":4767},"NCT00405366","Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer",[87],"2015-07",[3744],[589],{"trials":4769,"activeCount":100},[4770,4774,4781],{"nctId":576,"briefTitle":577,"status":229,"phases":4771,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":4772,"interventions":4773},[88],[584],[371,586,587,588,589],{"nctId":4775,"briefTitle":4776,"status":403,"phases":4777,"primaryCompletion":1097,"completion":4778,"start":1150,"enrollment":326,"conditions":4779,"interventions":4780},"NCT00767468","Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis",[88],"2010-11",[1112],[589],{"nctId":3522,"briefTitle":3523,"status":229,"phases":4782,"primaryCompletion":3525,"completion":3526,"start":3527,"enrollment":513,"conditions":4783,"interventions":4784},[88],[1112],[350,3530,589],{"trials":4786,"activeCount":100},[],{"trials":4788,"activeCount":100},[],{"trials":4790,"activeCount":100},[],{"trials":4792,"activeCount":100},[],{"intervention":4794,"totalTrials":233,"cells":4795},"Atorvastatin",{"EARLY_PHASE1":4796,"PHASE1":4805,"PHASE2":4817,"PHASE3":4819,"PHASE4":4821,"NA":4823},{"trials":4797,"activeCount":100},[4798],{"nctId":4799,"briefTitle":4800,"status":229,"phases":4801,"primaryCompletion":4802,"completion":4802,"start":3437,"enrollment":1016,"conditions":4803,"interventions":4804},"NCT02767362","A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium",[87],"2019-09-26",[34],[4794],{"trials":4806,"activeCount":100},[4807],{"nctId":4808,"briefTitle":4809,"status":973,"phases":4810,"primaryCompletion":4811,"completion":4812,"start":2161,"enrollment":100,"conditions":4813,"interventions":4815},"NCT01605344","Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI",[88],"2013-07","2014-07",[4814],"Advanced Adenocarcinoma of the Colon or Rectum",[4816,4794],"FOLFIRI.",{"trials":4818,"activeCount":100},[],{"trials":4820,"activeCount":100},[],{"trials":4822,"activeCount":100},[],{"trials":4824,"activeCount":100},[],{"intervention":4826,"totalTrials":233,"cells":4827},"clofarabine",{"EARLY_PHASE1":4828,"PHASE1":4830,"PHASE2":4850,"PHASE3":4852,"PHASE4":4854,"NA":4856},{"trials":4829,"activeCount":100},[],{"trials":4831,"activeCount":100},[4832,4841],{"nctId":4833,"briefTitle":4834,"status":403,"phases":4835,"primaryCompletion":1034,"completion":4836,"start":4837,"enrollment":3314,"conditions":4838,"interventions":4839},"NCT00577694","Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[88],"2015-08","2007-11",[3402],[4826,4840],"gemtuzumab ozogamicin",{"nctId":4842,"briefTitle":4843,"status":229,"phases":4844,"primaryCompletion":2161,"completion":963,"start":678,"enrollment":96,"conditions":4845,"interventions":4848},"NCT01169012","PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias",[88],[4846,1260,222,4847],"Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia",[4849],"Clofarabine",{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[],{"trials":4855,"activeCount":100},[],{"trials":4857,"activeCount":100},[],{"intervention":4859,"totalTrials":233,"cells":4860},"Artesunate pessary",{"EARLY_PHASE1":4861,"PHASE1":4863,"PHASE2":4887,"PHASE3":4889,"PHASE4":4891,"NA":4893},{"trials":4862,"activeCount":100},[],{"trials":4864,"activeCount":100},[4865,4876],{"nctId":4866,"briefTitle":4867,"status":229,"phases":4868,"primaryCompletion":4869,"completion":4869,"start":4870,"enrollment":35,"conditions":4871,"interventions":4875},"NCT06263582","Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya",[88],"2024-08-14","2024-05-29",[1492,4872,4873,4874],"Cervix Intraepithelial Neoplasia Grade 3","Cervix; Intraepithelial Neoplasia, Grade I","Cervix; Intraepithelial Neoplasia, Grade II",[4859],{"nctId":4877,"briefTitle":4878,"status":229,"phases":4879,"primaryCompletion":4880,"completion":4881,"start":4882,"enrollment":22,"conditions":4883,"interventions":4886},"NCT06165614","Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya",[88],"2025-01-30","2025-04-10","2024-03-04",[1492,4884,4885,3881],"Cervix Neoplasm","Precancerous Conditions",[4859],{"trials":4888,"activeCount":100},[],{"trials":4890,"activeCount":100},[],{"trials":4892,"activeCount":100},[],{"trials":4894,"activeCount":100},[],{"intervention":4816,"totalTrials":9,"cells":4896},{"EARLY_PHASE1":4897,"PHASE1":4899,"PHASE2":4905,"PHASE3":4907,"PHASE4":4909,"NA":4911},{"trials":4898,"activeCount":100},[],{"trials":4900,"activeCount":100},[4901],{"nctId":4808,"briefTitle":4809,"status":973,"phases":4902,"primaryCompletion":4811,"completion":4812,"start":2161,"enrollment":100,"conditions":4903,"interventions":4904},[88],[4814],[4816,4794],{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[],{"trials":4910,"activeCount":100},[],{"trials":4912,"activeCount":100},[],{"intervention":1076,"totalTrials":9,"cells":4914},{"EARLY_PHASE1":4915,"PHASE1":4917,"PHASE2":4923,"PHASE3":4925,"PHASE4":4927,"NA":4929},{"trials":4916,"activeCount":100},[],{"trials":4918,"activeCount":100},[4919],{"nctId":1065,"briefTitle":1066,"status":229,"phases":4920,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":4921,"interventions":4922},[88],[584],[1074,1075,634,1076,1058],{"trials":4924,"activeCount":100},[],{"trials":4926,"activeCount":100},[],{"trials":4928,"activeCount":100},[],{"trials":4930,"activeCount":100},[],{"intervention":4932,"totalTrials":9,"cells":4933},"CAR.CD30 T cells",{"EARLY_PHASE1":4934,"PHASE1":4936,"PHASE2":4949,"PHASE3":4951,"PHASE4":4953,"NA":4955},{"trials":4935,"activeCount":100},[],{"trials":4937,"activeCount":100},[4938],{"nctId":4939,"briefTitle":4940,"status":973,"phases":4941,"primaryCompletion":4942,"completion":4943,"start":4944,"enrollment":100,"conditions":4945,"interventions":4948},"NCT01316146","Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)",[88],"2016-01-28","2022-05-04","2011-10-03",[4946,4947],"Non-Hodgkin's Lymphoma","Hodgkin's Lymphoma",[4932],{"trials":4950,"activeCount":100},[],{"trials":4952,"activeCount":100},[],{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"intervention":4958,"totalTrials":9,"cells":4959},"Parsaclisib",{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4973,"PHASE3":4975,"PHASE4":4977,"NA":4979},{"trials":4961,"activeCount":100},[],{"trials":4963,"activeCount":100},[4964],{"nctId":4965,"briefTitle":4966,"status":973,"phases":4967,"primaryCompletion":4968,"completion":4968,"start":4969,"enrollment":100,"conditions":4970,"interventions":4972},"NCT04142554","Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer",[88],"2020-09-07","2020-06-01",[15,2823,169,4971],"HER2-positive Breast Cancer",[4958],{"trials":4974,"activeCount":100},[],{"trials":4976,"activeCount":100},[],{"trials":4978,"activeCount":100},[],{"trials":4980,"activeCount":100},[],{"intervention":4840,"totalTrials":9,"cells":4982},{"EARLY_PHASE1":4983,"PHASE1":4985,"PHASE2":4991,"PHASE3":4993,"PHASE4":4995,"NA":4997},{"trials":4984,"activeCount":100},[],{"trials":4986,"activeCount":100},[4987],{"nctId":4833,"briefTitle":4834,"status":403,"phases":4988,"primaryCompletion":1034,"completion":4836,"start":4837,"enrollment":3314,"conditions":4989,"interventions":4990},[88],[3402],[4826,4840],{"trials":4992,"activeCount":100},[],{"trials":4994,"activeCount":100},[],{"trials":4996,"activeCount":100},[],{"trials":4998,"activeCount":100},[],{"intervention":5000,"totalTrials":9,"cells":5001},"Intravaginal 5-Fluorouracil",{"EARLY_PHASE1":5002,"PHASE1":5004,"PHASE2":5015,"PHASE3":5017,"PHASE4":5019,"NA":5021},{"trials":5003,"activeCount":100},[],{"trials":5005,"activeCount":100},[5006],{"nctId":5007,"briefTitle":5008,"status":229,"phases":5009,"primaryCompletion":5010,"completion":5010,"start":5011,"enrollment":35,"conditions":5012,"interventions":5014},"NCT05362955","5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa",[88],"2024-02-01","2023-04-26",[5013,1490],"CIN 2\u002F3",[5000],{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[],{"trials":5020,"activeCount":100},[],{"trials":5022,"activeCount":100},[],{"intervention":313,"totalTrials":9,"cells":5024},{"EARLY_PHASE1":5025,"PHASE1":5027,"PHASE2":5033,"PHASE3":5035,"PHASE4":5037,"NA":5039},{"trials":5026,"activeCount":100},[],{"trials":5028,"activeCount":100},[5029],{"nctId":305,"briefTitle":306,"status":229,"phases":5030,"primaryCompletion":308,"completion":308,"start":309,"enrollment":205,"conditions":5031,"interventions":5032},[88],[15,311],[313,172],{"trials":5034,"activeCount":100},[],{"trials":5036,"activeCount":100},[],{"trials":5038,"activeCount":100},[],{"trials":5040,"activeCount":100},[],{"intervention":5042,"totalTrials":9,"cells":5043},"Temsirolimus",{"EARLY_PHASE1":5044,"PHASE1":5046,"PHASE2":5058,"PHASE3":5060,"PHASE4":5062,"NA":5064},{"trials":5045,"activeCount":100},[],{"trials":5047,"activeCount":100},[5048],{"nctId":5049,"briefTitle":5050,"status":403,"phases":5051,"primaryCompletion":1095,"completion":5052,"start":975,"enrollment":211,"conditions":5053,"interventions":5056},"NCT01204450","Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma",[88],"2013-03",[2900,128,5054,5055],"Sarcoma","Unspecified Childhood Solid Tumor, Protocol Specific",[5042,5057],"Valproic Acid",{"trials":5059,"activeCount":100},[],{"trials":5061,"activeCount":100},[],{"trials":5063,"activeCount":100},[],{"trials":5065,"activeCount":100},[],{"intervention":5057,"totalTrials":9,"cells":5067},{"EARLY_PHASE1":5068,"PHASE1":5070,"PHASE2":5076,"PHASE3":5078,"PHASE4":5080,"NA":5082},{"trials":5069,"activeCount":100},[],{"trials":5071,"activeCount":100},[5072],{"nctId":5049,"briefTitle":5050,"status":403,"phases":5073,"primaryCompletion":1095,"completion":5052,"start":975,"enrollment":211,"conditions":5074,"interventions":5075},[88],[2900,128,5054,5055],[5042,5057],{"trials":5077,"activeCount":100},[],{"trials":5079,"activeCount":100},[],{"trials":5081,"activeCount":100},[],{"trials":5083,"activeCount":100},[],{"intervention":5085,"totalTrials":9,"cells":5086},"Bavituximab",{"EARLY_PHASE1":5087,"PHASE1":5089,"PHASE2":5099,"PHASE3":5101,"PHASE4":5103,"NA":5105},{"trials":5088,"activeCount":100},[],{"trials":5090,"activeCount":100},[5091],{"nctId":5092,"briefTitle":5093,"status":229,"phases":5094,"primaryCompletion":5095,"completion":5096,"start":3137,"enrollment":445,"conditions":5097,"interventions":5098},"NCT01323062","Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects",[88],"2014-05-14","2018-10-01",[1230],[5085],{"trials":5100,"activeCount":100},[],{"trials":5102,"activeCount":100},[],{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"intervention":2839,"totalTrials":9,"cells":5108},{"EARLY_PHASE1":5109,"PHASE1":5111,"PHASE2":5117,"PHASE3":5119,"PHASE4":5121,"NA":5123},{"trials":5110,"activeCount":100},[],{"trials":5112,"activeCount":100},[5113],{"nctId":2831,"briefTitle":2832,"status":229,"phases":5114,"primaryCompletion":2834,"completion":2835,"start":2836,"enrollment":939,"conditions":5115,"interventions":5116},[88],[1749],[2839,2840,2841,2825,647],{"trials":5118,"activeCount":100},[],{"trials":5120,"activeCount":100},[],{"trials":5122,"activeCount":100},[],{"trials":5124,"activeCount":100},[],{"intervention":2841,"totalTrials":9,"cells":5126},{"EARLY_PHASE1":5127,"PHASE1":5129,"PHASE2":5135,"PHASE3":5137,"PHASE4":5139,"NA":5141},{"trials":5128,"activeCount":100},[],{"trials":5130,"activeCount":100},[5131],{"nctId":2831,"briefTitle":2832,"status":229,"phases":5132,"primaryCompletion":2834,"completion":2835,"start":2836,"enrollment":939,"conditions":5133,"interventions":5134},[88],[1749],[2839,2840,2841,2825,647],{"trials":5136,"activeCount":100},[],{"trials":5138,"activeCount":100},[],{"trials":5140,"activeCount":100},[],{"trials":5142,"activeCount":100},[],{"intervention":3583,"totalTrials":9,"cells":5144},{"EARLY_PHASE1":5145,"PHASE1":5147,"PHASE2":5153,"PHASE3":5155,"PHASE4":5157,"NA":5159},{"trials":5146,"activeCount":100},[],{"trials":5148,"activeCount":100},[5149],{"nctId":3573,"briefTitle":3574,"status":229,"phases":5150,"primaryCompletion":3576,"completion":3577,"start":3578,"enrollment":22,"conditions":5151,"interventions":5152},[88],[3580,3581,1331],[3583,3566],{"trials":5154,"activeCount":100},[],{"trials":5156,"activeCount":100},[],{"trials":5158,"activeCount":100},[],{"trials":5160,"activeCount":100},[],{"intervention":600,"totalTrials":9,"cells":5162},{"EARLY_PHASE1":5163,"PHASE1":5165,"PHASE2":5171,"PHASE3":5173,"PHASE4":5175,"NA":5177},{"trials":5164,"activeCount":100},[],{"trials":5166,"activeCount":100},[5167],{"nctId":591,"briefTitle":592,"status":229,"phases":5168,"primaryCompletion":594,"completion":595,"start":596,"enrollment":35,"conditions":5169,"interventions":5170},[88],[598],[600,461],{"trials":5172,"activeCount":100},[],{"trials":5174,"activeCount":100},[],{"trials":5176,"activeCount":100},[],{"trials":5178,"activeCount":100},[],{"intervention":5180,"totalTrials":9,"cells":5181},"Alisertib",{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5195,"PHASE3":5197,"PHASE4":5199,"NA":5201},{"trials":5183,"activeCount":100},[],{"trials":5185,"activeCount":100},[5186],{"nctId":5187,"briefTitle":5188,"status":403,"phases":5189,"primaryCompletion":4476,"completion":5190,"start":5191,"enrollment":9,"conditions":5192,"interventions":5194},"NCT02700022","A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas",[88],"2017-08-18","2016-10",[657,142,5193],"Burkitt Lymphoma",[5180],{"trials":5196,"activeCount":100},[],{"trials":5198,"activeCount":100},[],{"trials":5200,"activeCount":100},[],{"trials":5202,"activeCount":100},[],{"intervention":3530,"totalTrials":9,"cells":5204},{"EARLY_PHASE1":5205,"PHASE1":5207,"PHASE2":5213,"PHASE3":5215,"PHASE4":5217,"NA":5219},{"trials":5206,"activeCount":100},[],{"trials":5208,"activeCount":100},[5209],{"nctId":3522,"briefTitle":3523,"status":229,"phases":5210,"primaryCompletion":3525,"completion":3526,"start":3527,"enrollment":513,"conditions":5211,"interventions":5212},[88],[1112],[350,3530,589],{"trials":5214,"activeCount":100},[],{"trials":5216,"activeCount":100},[],{"trials":5218,"activeCount":100},[],{"trials":5220,"activeCount":100},[],{"intervention":425,"totalTrials":9,"cells":5222},{"EARLY_PHASE1":5223,"PHASE1":5225,"PHASE2":5231,"PHASE3":5233,"PHASE4":5235,"NA":5237},{"trials":5224,"activeCount":100},[],{"trials":5226,"activeCount":100},[5227],{"nctId":413,"briefTitle":414,"status":415,"phases":5228,"primaryCompletion":417,"completion":418,"start":419,"enrollment":326,"conditions":5229,"interventions":5230},[88],[421,422,423],[425,56],{"trials":5232,"activeCount":100},[],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"intervention":813,"totalTrials":9,"cells":5240},{"EARLY_PHASE1":5241,"PHASE1":5243,"PHASE2":5249,"PHASE3":5251,"PHASE4":5253,"NA":5255},{"trials":5242,"activeCount":100},[],{"trials":5244,"activeCount":100},[5245],{"nctId":804,"briefTitle":805,"status":403,"phases":5246,"primaryCompletion":807,"completion":808,"start":809,"enrollment":9,"conditions":5247,"interventions":5248},[88],[811],[46,645,813,814,815],{"trials":5250,"activeCount":100},[],{"trials":5252,"activeCount":100},[],{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[],{"intervention":815,"totalTrials":9,"cells":5258},{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5267,"PHASE3":5269,"PHASE4":5271,"NA":5273},{"trials":5260,"activeCount":100},[],{"trials":5262,"activeCount":100},[5263],{"nctId":804,"briefTitle":805,"status":403,"phases":5264,"primaryCompletion":807,"completion":808,"start":809,"enrollment":9,"conditions":5265,"interventions":5266},[88],[811],[46,645,813,814,815],{"trials":5268,"activeCount":100},[],{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[],{"intervention":3617,"totalTrials":9,"cells":5276},{"EARLY_PHASE1":5277,"PHASE1":5279,"PHASE2":5285,"PHASE3":5287,"PHASE4":5289,"NA":5291},{"trials":5278,"activeCount":100},[],{"trials":5280,"activeCount":100},[5281],{"nctId":3612,"briefTitle":3613,"status":229,"phases":5282,"primaryCompletion":3346,"completion":3347,"start":1036,"enrollment":139,"conditions":5283,"interventions":5284},[88],[15],[3605,3617,3618,3619],{"trials":5286,"activeCount":100},[],{"trials":5288,"activeCount":100},[],{"trials":5290,"activeCount":100},[],{"trials":5292,"activeCount":100},[],{"intervention":3619,"totalTrials":9,"cells":5294},{"EARLY_PHASE1":5295,"PHASE1":5297,"PHASE2":5303,"PHASE3":5305,"PHASE4":5307,"NA":5309},{"trials":5296,"activeCount":100},[],{"trials":5298,"activeCount":100},[5299],{"nctId":3612,"briefTitle":3613,"status":229,"phases":5300,"primaryCompletion":3346,"completion":3347,"start":1036,"enrollment":139,"conditions":5301,"interventions":5302},[88],[15],[3605,3617,3618,3619],{"trials":5304,"activeCount":100},[],{"trials":5306,"activeCount":100},[],{"trials":5308,"activeCount":100},[],{"trials":5310,"activeCount":100},[],{"intervention":3176,"totalTrials":9,"cells":5312},{"EARLY_PHASE1":5313,"PHASE1":5315,"PHASE2":5321,"PHASE3":5323,"PHASE4":5325,"NA":5327},{"trials":5314,"activeCount":100},[],{"trials":5316,"activeCount":100},[5317],{"nctId":3171,"briefTitle":3172,"status":229,"phases":5318,"primaryCompletion":581,"completion":1150,"start":2911,"enrollment":126,"conditions":5319,"interventions":5320},[88],[584],[1089,3176],{"trials":5322,"activeCount":100},[],{"trials":5324,"activeCount":100},[],{"trials":5326,"activeCount":100},[],{"trials":5328,"activeCount":100},[],{"intervention":2967,"totalTrials":9,"cells":5330},{"EARLY_PHASE1":5331,"PHASE1":5333,"PHASE2":5339,"PHASE3":5341,"PHASE4":5343,"NA":5345},{"trials":5332,"activeCount":100},[],{"trials":5334,"activeCount":100},[5335],{"nctId":2959,"briefTitle":2960,"status":403,"phases":5336,"primaryCompletion":2962,"completion":2963,"start":1150,"enrollment":1351,"conditions":5337,"interventions":5338},[88],[2965],[1156,2967,2968],{"trials":5340,"activeCount":100},[],{"trials":5342,"activeCount":100},[],{"trials":5344,"activeCount":100},[],{"trials":5346,"activeCount":100},[],{"intervention":5348,"totalTrials":9,"cells":5349},"Perflutren lipid",{"EARLY_PHASE1":5350,"PHASE1":5359,"PHASE2":5361,"PHASE3":5363,"PHASE4":5365,"NA":5367},{"trials":5351,"activeCount":100},[5352],{"nctId":5353,"briefTitle":5354,"status":229,"phases":5355,"primaryCompletion":3437,"completion":3437,"start":1068,"enrollment":5356,"conditions":5357,"interventions":5358},"NCT01751529","Open-label Pilot Evaluating Renal Lesions w\u002F Contrast-enhaced US in Patients w\u002F Renal Cancer",[87],48,[3744],[5348],{"trials":5360,"activeCount":100},[],{"trials":5362,"activeCount":100},[],{"trials":5364,"activeCount":100},[],{"trials":5366,"activeCount":100},[],{"trials":5368,"activeCount":100},[],{"intervention":5370,"totalTrials":9,"cells":5371},"GSK1120212",{"EARLY_PHASE1":5372,"PHASE1":5381,"PHASE2":5383,"PHASE3":5385,"PHASE4":5387,"NA":5389},{"trials":5373,"activeCount":100},[5374],{"nctId":5375,"briefTitle":5376,"status":229,"phases":5377,"primaryCompletion":5378,"completion":5378,"start":962,"enrollment":27,"conditions":5379,"interventions":5380},"NCT01467310","Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212",[87],"2016-03-21",[15],[5370],{"trials":5382,"activeCount":100},[],{"trials":5384,"activeCount":100},[],{"trials":5386,"activeCount":100},[],{"trials":5388,"activeCount":100},[],{"trials":5390,"activeCount":100},[],{"intervention":5392,"totalTrials":9,"cells":5393},"Mirtazapine",{"EARLY_PHASE1":5394,"PHASE1":5406,"PHASE2":5408,"PHASE3":5410,"PHASE4":5412,"NA":5414},{"trials":5395,"activeCount":100},[5396],{"nctId":5397,"briefTitle":5398,"status":229,"phases":5399,"primaryCompletion":3578,"completion":5400,"start":5401,"enrollment":3314,"conditions":5402,"interventions":5404},"NCT01725048","Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer",[87],"2013-10","2011-01",[5403,187],"Major Depressive Disorder",[5392,5405],"Citalopram",{"trials":5407,"activeCount":100},[],{"trials":5409,"activeCount":100},[],{"trials":5411,"activeCount":100},[],{"trials":5413,"activeCount":100},[],{"trials":5415,"activeCount":100},[],{"intervention":5405,"totalTrials":9,"cells":5417},{"EARLY_PHASE1":5418,"PHASE1":5424,"PHASE2":5426,"PHASE3":5428,"PHASE4":5430,"NA":5432},{"trials":5419,"activeCount":100},[5420],{"nctId":5397,"briefTitle":5398,"status":229,"phases":5421,"primaryCompletion":3578,"completion":5400,"start":5401,"enrollment":3314,"conditions":5422,"interventions":5423},[87],[5403,187],[5392,5405],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[],{"trials":5429,"activeCount":100},[],{"trials":5431,"activeCount":100},[],{"trials":5433,"activeCount":100},[],{"intervention":2826,"totalTrials":9,"cells":5435},{"EARLY_PHASE1":5436,"PHASE1":5442,"PHASE2":5444,"PHASE3":5446,"PHASE4":5448,"NA":5450},{"trials":5437,"activeCount":100},[5438],{"nctId":2817,"briefTitle":2818,"status":229,"phases":5439,"primaryCompletion":2820,"completion":2820,"start":2821,"enrollment":445,"conditions":5440,"interventions":5441},[87],[2823],[2825,2826,2827],{"trials":5443,"activeCount":100},[],{"trials":5445,"activeCount":100},[],{"trials":5447,"activeCount":100},[],{"trials":5449,"activeCount":100},[],{"trials":5451,"activeCount":100},[],{"intervention":5453,"totalTrials":9,"cells":5454},"Fluorothymidine",{"EARLY_PHASE1":5455,"PHASE1":5466,"PHASE2":5468,"PHASE3":5470,"PHASE4":5472,"NA":5474},{"trials":5456,"activeCount":100},[5457],{"nctId":5458,"briefTitle":5459,"status":403,"phases":5460,"primaryCompletion":5461,"completion":5461,"start":5462,"enrollment":395,"conditions":5463,"interventions":5465},"NCT03546556","18-FLT PET\u002FMR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients",[87],"2020-03-12","2017-01-01",[5464],"Graft Vs Host Disease",[5453],{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[],{"trials":5473,"activeCount":100},[],{"trials":5475,"activeCount":100},[],{"intervention":1114,"totalTrials":655,"cells":5477},{"EARLY_PHASE1":5478,"PHASE1":5480,"PHASE2":5486,"PHASE3":5500,"PHASE4":5502,"NA":5504},{"trials":5479,"activeCount":100},[],{"trials":5481,"activeCount":100},[5482],{"nctId":2831,"briefTitle":2832,"status":229,"phases":5483,"primaryCompletion":2834,"completion":2835,"start":2836,"enrollment":939,"conditions":5484,"interventions":5485},[88],[1749],[2839,2840,2841,2825,647],{"trials":5487,"activeCount":100},[5488,5492,5496],{"nctId":1106,"briefTitle":1107,"status":229,"phases":5489,"primaryCompletion":1097,"completion":1109,"start":1110,"enrollment":247,"conditions":5490,"interventions":5491},[89],[1112],[979,1114,1058],{"nctId":2735,"briefTitle":2736,"status":229,"phases":5493,"primaryCompletion":2738,"completion":2739,"start":2740,"conditions":5494,"interventions":5495},[88,89],[15],[349,1114,351],{"nctId":4621,"briefTitle":4622,"status":403,"phases":5497,"primaryCompletion":4624,"completion":4625,"start":546,"enrollment":1351,"conditions":5498,"interventions":5499},[88,89],[4627],[4612,2840],{"trials":5501,"activeCount":100},[],{"trials":5503,"activeCount":100},[],{"trials":5505,"activeCount":100},[5506],{"nctId":5507,"briefTitle":5508,"status":229,"phases":5509,"primaryCompletion":5510,"completion":5510,"start":5511,"enrollment":939,"conditions":5512,"interventions":5513},"NCT00280761","Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy",[],"2021-09-19","2003-12",[26],[1114,5514],"5-fluorouracil",{"intervention":3410,"totalTrials":264,"cells":5516},{"EARLY_PHASE1":5517,"PHASE1":5519,"PHASE2":5521,"PHASE3":5531,"PHASE4":5533,"NA":5535},{"trials":5518,"activeCount":100},[],{"trials":5520,"activeCount":100},[],{"trials":5522,"activeCount":100},[5523,5527],{"nctId":3393,"briefTitle":3394,"status":229,"phases":5524,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":3399,"conditions":5525,"interventions":5526},[89],[3401,3402,21,2965,3403],[3405,2871,3406,3407,3408,3409,3410],{"nctId":3434,"briefTitle":3435,"status":229,"phases":5528,"primaryCompletion":3437,"completion":3437,"start":3438,"enrollment":3439,"conditions":5529,"interventions":5530},[88,89],[3401,3402,21,2965,3403],[3442,3406,3407,3408,3410,3409],{"trials":5532,"activeCount":100},[],{"trials":5534,"activeCount":100},[],{"trials":5536,"activeCount":100},[5537],{"nctId":5538,"briefTitle":5539,"status":229,"phases":5540,"primaryCompletion":5541,"completion":5541,"start":5542,"enrollment":788,"conditions":5543,"interventions":5545},"NCT04645667","Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)",[],"2023-10-15","2021-02-01",[5544],"Acute GVHD",[5546],"Tacrolimus",{"intervention":3618,"totalTrials":264,"cells":5548},{"EARLY_PHASE1":5549,"PHASE1":5551,"PHASE2":5557,"PHASE3":5563,"PHASE4":5565,"NA":5567},{"trials":5550,"activeCount":100},[],{"trials":5552,"activeCount":100},[5553],{"nctId":3612,"briefTitle":3613,"status":229,"phases":5554,"primaryCompletion":3346,"completion":3347,"start":1036,"enrollment":139,"conditions":5555,"interventions":5556},[88],[15],[3605,3617,3618,3619],{"trials":5558,"activeCount":100},[5559],{"nctId":4003,"briefTitle":4004,"status":229,"phases":5560,"primaryCompletion":4006,"completion":4007,"start":4008,"enrollment":4009,"conditions":5561,"interventions":5562},[89],[15,4011],[3994,3618],{"trials":5564,"activeCount":100},[],{"trials":5566,"activeCount":100},[],{"trials":5568,"activeCount":100},[5569],{"nctId":5570,"briefTitle":5571,"status":229,"phases":5572,"primaryCompletion":963,"completion":5573,"start":2910,"enrollment":5574,"conditions":5575,"interventions":5576},"NCT01138345","Biomarkers in Blood Samples From Older Breast Cancer Survivors",[],"2014-02",246,[15],[3618,5577],"reverse transcriptase-polymerase chain reaction",{"intervention":1300,"totalTrials":233,"cells":5579},{"EARLY_PHASE1":5580,"PHASE1":5582,"PHASE2":5584,"PHASE3":5590,"PHASE4":5592,"NA":5594},{"trials":5581,"activeCount":100},[],{"trials":5583,"activeCount":100},[],{"trials":5585,"activeCount":100},[5586],{"nctId":1291,"briefTitle":1292,"status":229,"phases":5587,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":1296,"conditions":5588,"interventions":5589},[89],[1298],[1300,1131,1301,1302],{"trials":5591,"activeCount":100},[],{"trials":5593,"activeCount":100},[],{"trials":5595,"activeCount":100},[5596],{"nctId":5507,"briefTitle":5508,"status":229,"phases":5597,"primaryCompletion":5510,"completion":5510,"start":5511,"enrollment":939,"conditions":5598,"interventions":5599},[],[26],[1114,5514],{"intervention":5601,"totalTrials":9,"cells":5602},"Neratinib",{"EARLY_PHASE1":5603,"PHASE1":5605,"PHASE2":5607,"PHASE3":5609,"PHASE4":5611,"NA":5613},{"trials":5604,"activeCount":100},[],{"trials":5606,"activeCount":100},[],{"trials":5608,"activeCount":100},[],{"trials":5610,"activeCount":100},[],{"trials":5612,"activeCount":100},[],{"trials":5614,"activeCount":100},[5615],{"nctId":5616,"briefTitle":5617,"status":274,"phases":5618,"primaryCompletion":1096,"completion":1342,"start":4811,"conditions":5619,"interventions":5620},"NCT01956253","Single Subject Neratinib in Bladder Cancer (NRR)",[],[29],[5601],{"intervention":279,"totalTrials":9,"cells":5622},{"EARLY_PHASE1":5623,"PHASE1":5625,"PHASE2":5627,"PHASE3":5629,"PHASE4":5631,"NA":5633},{"trials":5624,"activeCount":100},[],{"trials":5626,"activeCount":100},[],{"trials":5628,"activeCount":100},[],{"trials":5630,"activeCount":100},[],{"trials":5632,"activeCount":100},[],{"trials":5634,"activeCount":100},[5635],{"nctId":272,"briefTitle":273,"status":274,"phases":5636,"conditions":5637,"interventions":5638},[],[277],[279,149,95],{"intervention":5640,"totalTrials":9,"cells":5641},"5 Fluorouracil (5 FU) Cream",{"EARLY_PHASE1":5642,"PHASE1":5644,"PHASE2":5646,"PHASE3":5648,"PHASE4":5650,"NA":5652},{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[],{"trials":5647,"activeCount":100},[],{"trials":5649,"activeCount":100},[],{"trials":5651,"activeCount":100},[],{"trials":5653,"activeCount":100},[5654],{"nctId":5655,"briefTitle":5656,"status":229,"phases":5657,"primaryCompletion":5658,"completion":5658,"start":5659,"enrollment":5660,"conditions":5661,"interventions":5663},"NCT05413811","Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV",[92],"2025-06-30","2023-03-22",180,[5662,1493,1494,3879,3880],"Cervical Cancer",[5640],{"intervention":5577,"totalTrials":9,"cells":5665},{"EARLY_PHASE1":5666,"PHASE1":5668,"PHASE2":5670,"PHASE3":5672,"PHASE4":5674,"NA":5676},{"trials":5667,"activeCount":100},[],{"trials":5669,"activeCount":100},[],{"trials":5671,"activeCount":100},[],{"trials":5673,"activeCount":100},[],{"trials":5675,"activeCount":100},[],{"trials":5677,"activeCount":100},[5678],{"nctId":5570,"briefTitle":5571,"status":229,"phases":5679,"primaryCompletion":963,"completion":5573,"start":2910,"enrollment":5574,"conditions":5680,"interventions":5681},[],[15],[3618,5577],{"intervention":5683,"totalTrials":9,"cells":5684},"androgen receptor signaling inhibitors",{"EARLY_PHASE1":5685,"PHASE1":5687,"PHASE2":5689,"PHASE3":5691,"PHASE4":5693,"NA":5695},{"trials":5686,"activeCount":100},[],{"trials":5688,"activeCount":100},[],{"trials":5690,"activeCount":100},[],{"trials":5692,"activeCount":100},[],{"trials":5694,"activeCount":100},[],{"trials":5696,"activeCount":100},[5697],{"nctId":5698,"briefTitle":5699,"status":229,"phases":5700,"primaryCompletion":5701,"completion":5701,"start":5702,"enrollment":1016,"conditions":5703,"interventions":5705},"NCT05612880","Physical Function During ARSI Treatment",[],"2024-11-06","2022-10-13",[5704],"Advanced Prostate Carcinoma",[5683],{"intervention":5707,"totalTrials":9,"cells":5708},"FLT PET\u002FMR",{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5710,"activeCount":100},[],{"trials":5712,"activeCount":100},[],{"trials":5714,"activeCount":100},[],{"trials":5716,"activeCount":100},[],{"trials":5718,"activeCount":100},[],{"trials":5720,"activeCount":100},[5721],{"nctId":5722,"briefTitle":5723,"status":973,"phases":5724,"primaryCompletion":5725,"completion":5725,"start":5726,"enrollment":100,"conditions":5727,"interventions":5731},"NCT02328300","FLT PET\u002FMR for Evaluation of Pseudoprogression in Patients With Brain Lesions",[],"2018-07-31","2014-05-07",[5728,5729,5730],"Brain Lesions","Brain Metastasis","Brain Metastases",[5707],{"intervention":2165,"totalTrials":9,"cells":5733},{"EARLY_PHASE1":5734,"PHASE1":5736,"PHASE2":5738,"PHASE3":5740,"PHASE4":5742,"NA":5744},{"trials":5735,"activeCount":100},[],{"trials":5737,"activeCount":100},[],{"trials":5739,"activeCount":100},[],{"trials":5741,"activeCount":100},[],{"trials":5743,"activeCount":100},[],{"trials":5745,"activeCount":100},[5746],{"nctId":2156,"briefTitle":2157,"status":229,"phases":5747,"primaryCompletion":2159,"completion":2160,"start":2161,"enrollment":2162,"conditions":5748,"interventions":5749},[92],[277],[2137,2165],{"intervention":5751,"totalTrials":9,"cells":5752},"Bosutinib",{"EARLY_PHASE1":5753,"PHASE1":5755,"PHASE2":5757,"PHASE3":5759,"PHASE4":5761,"NA":5763},{"trials":5754,"activeCount":100},[],{"trials":5756,"activeCount":100},[],{"trials":5758,"activeCount":100},[],{"trials":5760,"activeCount":100},[],{"trials":5762,"activeCount":100},[],{"trials":5764,"activeCount":100},[5765],{"nctId":5766,"briefTitle":5767,"status":229,"phases":5768,"primaryCompletion":5769,"completion":5769,"start":5770,"enrollment":457,"conditions":5771,"interventions":5777},"NCT03885830","Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients",[],"2022-06-15","2019-06-20",[5772,5773,5774,5775,5776],"CML, Chronic Phase","CML (Chronic Myelogenous Leukemia","CML - Philadelphia Chromosome","Chronic Myeloid Leukemia","Chronic Myeloid Leukemia, Chronic Phase",[5751,5778,5779,5780],"Dasatinib","Imatinib","Nilotinib",{"intervention":5778,"totalTrials":9,"cells":5782},{"EARLY_PHASE1":5783,"PHASE1":5785,"PHASE2":5787,"PHASE3":5789,"PHASE4":5791,"NA":5793},{"trials":5784,"activeCount":100},[],{"trials":5786,"activeCount":100},[],{"trials":5788,"activeCount":100},[],{"trials":5790,"activeCount":100},[],{"trials":5792,"activeCount":100},[],{"trials":5794,"activeCount":100},[5795],{"nctId":5766,"briefTitle":5767,"status":229,"phases":5796,"primaryCompletion":5769,"completion":5769,"start":5770,"enrollment":457,"conditions":5797,"interventions":5798},[],[5772,5773,5774,5775,5776],[5751,5778,5779,5780],{"intervention":5779,"totalTrials":9,"cells":5800},{"EARLY_PHASE1":5801,"PHASE1":5803,"PHASE2":5805,"PHASE3":5807,"PHASE4":5809,"NA":5811},{"trials":5802,"activeCount":100},[],{"trials":5804,"activeCount":100},[],{"trials":5806,"activeCount":100},[],{"trials":5808,"activeCount":100},[],{"trials":5810,"activeCount":100},[],{"trials":5812,"activeCount":100},[5813],{"nctId":5766,"briefTitle":5767,"status":229,"phases":5814,"primaryCompletion":5769,"completion":5769,"start":5770,"enrollment":457,"conditions":5815,"interventions":5816},[],[5772,5773,5774,5775,5776],[5751,5778,5779,5780],{"intervention":5780,"totalTrials":9,"cells":5818},{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5825,"PHASE4":5827,"NA":5829},{"trials":5820,"activeCount":100},[],{"trials":5822,"activeCount":100},[],{"trials":5824,"activeCount":100},[],{"trials":5826,"activeCount":100},[],{"trials":5828,"activeCount":100},[],{"trials":5830,"activeCount":100},[5831],{"nctId":5766,"briefTitle":5767,"status":229,"phases":5832,"primaryCompletion":5769,"completion":5769,"start":5770,"enrollment":457,"conditions":5833,"interventions":5834},[],[5772,5773,5774,5775,5776],[5751,5778,5779,5780],{"intervention":5836,"totalTrials":9,"cells":5837},"efalizumab",{"EARLY_PHASE1":5838,"PHASE1":5840,"PHASE2":5842,"PHASE3":5844,"PHASE4":5846,"NA":5848},{"trials":5839,"activeCount":100},[],{"trials":5841,"activeCount":100},[],{"trials":5843,"activeCount":100},[],{"trials":5845,"activeCount":100},[],{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[5850],{"nctId":5851,"briefTitle":5852,"status":403,"phases":5853,"primaryCompletion":5854,"completion":1150,"start":4672,"enrollment":233,"conditions":5855,"interventions":5857},"NCT00489216","Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids",[92],"2008-06",[5856],"Graft Versus Host Disease",[5836]]